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8Executive Summary
The physical, psychological and social
implications of opiate dependency are well
known. A variety of treatment approaches,
including behavioural therapy, social skills and
stress management have been used. The
pharmacotherapeutic approach, using
methadone maintenance therapy, has proved
most beneficial to date and is the mainstay of
treatment in the Irish setting.
A systematic review was undertaken in order
to evaluate the potential usefulness of
buprenorphine as an intervention in the
treatment of opiate dependency. All available
data were retrieved by means of a
comprehensive search of the published
literature and clinical trials databases. Authors
of pivotal studies were contacted for further
information, for inclusion in a meta analysis.
Contact was made with experts in the UK and
France, to evaluate the practical issues
associated with buprenorphine in a clinical
setting. Pharmacoeconomic data were
retrieved from the GMS, ERHA and the
manufacturer for the purposes of analysis.
The results of the clinical trials evaluation
showed that buprenorphine appeared to 
have potential in the management of opiate
dependence. It was shown to be at least 
as effective as other treatment regimens
(clonidine and lofexidine) in treating managed
opiate withdrawal (detoxification).
Buprenorphine (at doses of >8mg/day) was 
as effective as methadone as a maintenance
treatment option. It was not possible to
define the optimal dosage regimen for either
indication, but treatment appeared to be 
most effective when dosage was titrated to
the individual’s needs. Because of its
pharmacological profile, less than daily dosing
(e.g. thrice weekly) is a possible dosing option.
Evaluation of its use in clinical practice
showed that it was considered as effective 
as methadone for maintenance treatment, 
had a better safety profile but had more abuse
potential. Accordingly, supervised dispensing
was recommended by many experts, especially
in the early months of treatment. Experience
of its use in managed opiate withdrawal was
more limited but was also favourable. 
The review suggests that buprenorphine may
be viewed as an effective treatment option 
in the management of opiate dependence
syndrome, with an acceptable safety profile. 
9Opiate derivatives, including heroin, opium
and morphine became available on the
European illegal drug markets from the late
1960s. Illicit opiate use increased during the
1970s and became a major problem in the
1980s, because of its association with the
HIV/AIDS epidemic (Farrell et al, 2000).
Current EU figures for problem drug use
(defined as injecting drug use or long-
duration/regular use of opiates, cocaine
and/or amphetamines) range from 2-3:1,000 to
5-8:1,000 inhabitants, aged between 15 and 64
years (EMCDDA, 2001). Ireland’s rate is
intermediate at 3-5:1,000. Heroin is the main
substance of problem drug use in the EU
(National Drugs Strategy, 2001). 
It is estimated that about one quarter of
people who have ever used heroin develop
dependence (Ward et al, 1999).
Many countries have introduced drug treatment
programmes. However, the nature and extent 
of these programmes vary considerably from
country to country. In 2000, it was estimated
that over 300,000 drug users in the EU were
receiving substitution treatment, compared
with 110,000 in the USA and 20,000 in Australia
(Farrell et al, 2000). 
Methadone substitution is the most widely
available maintenance treatment. There are,
however, certain disadvantages associated
with methadone therapy, including (a) the risk
of fatal respiratory depression in overdose,
because of its full agonist properties (b) the
inconvenience of daily dosing and daily
attendance at clinics, which makes it
unattractive to some patients and (c) the risk
of diversion of take-away doses (Mattick et al,
1998). Levo-alpha-acetyl-methadol (LAAM) has
been used in several EU countries and in the
USA in recent years. It has the advantage of
thrice weekly dosing. However, in 2001, the EU
Committee for Proprietary Medicinal Products
(scientific committee of the European
Medicines Evaluation Agency – EMEA)
suspended the marketing authorisation for
LAAM, on safety grounds (EMEA Public
Statement, 2001). 
Buprenorphine was introduced into the
maintenance treatment programmes of 
several EU countries since 1996 and France, 
in particular, has extensive clinical experience
with its use in both primary care and specialist
clinic settings. Other agents, such as heroin
and slow release morphine have been used,
under trial conditions only, in some countries.
Illicit opiate use became a public health
problem in Dublin in the early 1980s.
Methadone treatment was available during the
l980s but only in a limited fashion. Following 
a series of government initiatives in the 1990s,
the availability of methadone maintenance
treatment was extended (Barry, 2000). The
Drug Misuse Research Division of the Health
Research Board is responsible for operating
the National Drug Treatment Reporting
System (NDTRS), which is the main source of
information on drug misuse in Ireland. In its
statistical bulletin for 1997 and 1998 (NDTRS,
2000), it noted that 85% of all clients receiving
treatment for drug misuse were in the former
Eastern Health Board area and of these, heroin
was the main drug of misuse in approximately
70% of cases. 
As of December 2000, 5,032 individuals were
registered on the Central Drug Treatment List
(which is compiled by the Eastern Regional
Health Authority and is the only methadone
maintenance register at present) to avail of
methadone maintenance therapy (National 
Drug Strategy, 2001). The figure for the end of
February 2002, was 5,958 (personal
communication, Central Drug Treatment List).
This constitutes a large treatment cohort and
therefore any initiative, which would improve or
extend availability of treatment, would be of
benefit.
In June 2001, Mr Eoin Ryan, the Minister of
State for Local Development with special
responsibility for the National Drugs Strategy,
asked the National Advisory Committee on
Drugs (NACD) to undertake “research on the
effectiveness of buprenorphine as a form of
treatment for opiate addiction”. As a result, 
the NACD commissioned this review.
Introduction
Chapter 1
This review will evaluate the usefulness of
buprenorphine as an intervention in the
treatment of opiate dependence syndrome, 
in terms of effectiveness, safety in use, and
practical and pharmacoeconomic implications.
Where appropriate, comparison will be made
with methadone, the mainstay of treatment, in
order to more clearly define its potential role
in the Irish setting.
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The aim of this review was to evaluate the
effectiveness of buprenorphine as an
intervention in the treatment of Opiate
Dependence Syndrome.
The objectives of the review were to
1. identify all sources of information (both
published and unpublished) relating to
buprenorphine and in particular to its use
in the management of opiate dependency,
2. retrieve all relevant information for the
purposes of formal evaluation, including
those in languages other than English,
3. undertake a review of the pharmacology
of buprenorphine, including its potential
for interaction, using both preclinical and
clinical data,
4. undertake a systematic review and if
possible, formal meta-analysis of the
clinical trials, which evaluate the efficacy
of buprenorphine, in the management of
opiate dependency,
5. evaluate the safety of use of
buprenorphine, including the abuse
potential, using data from preclinical and
clinical studies and from real life usage,
6. investigate the usefulness of
buprenorphine in certain sub-groups of
opioid-dependent subjects, including its
potential use during pregnancy,
7. undertake a pharmacoeconomic analysis
to evaluate the cost-benefit of use of
buprenorphine in the management of
opiate dependence syndrome and, 
8. assess the implication of the use of
buprenorphine as an intervention in the
treatment of opiate dependence in
Ireland.
Aims and Objectives of the Review
Chapter 2
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Primary and review articles, abstracts and
other published information on buprenorphine
were identified using the following sources – 
• Medline, Pharmline, Micromedex, Iowa Drug
Information Service, (computerised indexing
and retrieval systems)
• Inpharma, Drugs and Therapy Perspectives
(abstracting and current awareness
publications)
Review journals (such as Drugs) and reference
textbooks (Martindale 32nd edition,
“Pharmacological Basis of Therapeutics”
Goodman and Gilman 10th Edition) were also
searched for background pharmacology.
Clinical Trials registers in the UK and USA
(www.controlled-trials.com; www.clinicaltrials.gov)
were searched to get information on ongoing
studies with buprenorphine, and the
manufacturer was asked to provide (a) all
adverse drug reaction data collected from
post-marketing surveillance studies in order 
to evaluate the safety profile with real life
usage and (b) information on pre-clinical
studies from the drug development dossier. 
The search terms used were as follows –
buprenorphine, opiate, opioid, addiction,
therapeutic, maintenance, withdrawal,
methadone and heroin. These were employed
separately and in combination with one
another. The reference lists of relevant articles
and reviews were examined for further reports.
No time limit was put on the earliest date for
acceptability of data and studies were evaluated
from 1978 onwards. The data lock point for
inclusion in the review was the 31st December
2001. Articles that became available after that
time were taken into account if they were
judged to provide additional information, which
might influence the outcome of the review.
Once identified, all papers were evaluated for
relevance to the review. Papers in languages
other than English were included if they were
considered to be relevant to the review.
Data from randomised controlled clinical trials
were pooled and included, if appropriate, in 
a meta analysis to compare the efficacy of
sublingual buprenorphine with oral methadone
in the management of opiate dependence. 
A meta analysis is a statistical technique for
combining the results of independent studies,
to present an objective and quantitative
measure of effectiveness of an intervention. It
reduces the chances of Type II errors by pooling
the data across several smaller studies and
therefore increases the confidence with which
the efficacy of an intervention can be assessed
(Sutton et al, 1999; Chalmers & Altman, 1995).
The data were systematically reviewed to
determine the optimal dosing regimen for
buprenorphine and to see if it might be more
effective for specific sub-groups of patients.
Safety was assessed using preclinical data as well
as pharmacovigilance data from clinical usage.
Articles, reviews and other papers relating to
the economic impact of buprenorphine were
retrieved for evaluation. The manufacturer was
asked to provide data on pharmacoeconomics
relating to its specific product Subutex®.
Information on current cost estimates for the
treatment of opiate dependence was sought
from the Eastern Regional Health Authority
(ERHA) and the General Medical Services
(GMS). These data were used in the
pharmacoeconomic evaluation.
Finally, in order to identify the practicalities of
use of buprenorphine, healthcare professionals,
experienced in the use of buprenorphine for
the management of opioid dependence, were
identified in the UK, France and Australia and
contacted for further specific data on the
advantages and disadvantages of
buprenorphine use in clinical practice.
Research Methodology of the Review
Chapter 3
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4.1 Introduction
Buprenorphine hydrochloride (Subutex®,
Buprenex®, Temgesic®) C29 H41 NO4. HCL.
[5α, 7α, (S) – 17 – (Cyclopropylmethyl) –α– 
(1,1-dimethylethye) – 4, 5 – epoxy – 18, 19 –
dihydro – 3 – hydroxy-6 – methoxy – L –
methyl – 6, 14 – etheno – morphinan – 7 –
methanol. 
Figure 1
Buprenorphine is a partial opiate agonist
analgesic. It acts as a partial agonist at the
opioid µ receptor, which mediates analgesia,
respiratory depression and reduced
gastrointestinal motility. It acts as an
antagonist at the k opiate receptors. As a
partial agonist, buprenorphine displays a bell
shaped dose response curve, with subjective
opiate-like effects reaching a maximum at a
dose of about 1mg (subcutaneously) in man
(Heel et al, 1979). Experimental evidence
suggests a ceiling on the ability of the drug 
to depress the respiratory system following
overdose, which may reflect a combination 
of extensive drug metabolism and the basic
pharmacology outlined above. Walsh et al
(1994) administered single sublingual doses 
of up to 32mg buprenorphine (equivalent to
1000mg of oral methadone) to non-opioid
dependent volunteers and noted only
marginal effects on respiratory function, as
measured by respiratory rate and oxygen
saturation. This represented a dose of 70 times
the recommended analgesic dose at the time.
This supported the safety of buprenorphine. 
Buprenorphine associates with opioid
receptors slowly but with high affinity and
dissociation from the receptor site is (pseudo)
irreversible (Lewis, 1985). Therefore, its effects
may be prolonged with potential implications
in relation to frequency of administration e.g.
alternate days. The study by Walsh et al
outlined above (1994) recorded plasma levels
comparable to “therapeutic” maintenance
levels (8mg/day) at 96 hours, after the 32mg
dose. Furthermore some of the opioid agonist
effects (such as pupillary constriction) also
lasted for 48 – 96 hours, in a dose-related
manner. This supported the feasibility of less
than daily administration as the lower toxicity
noted with buprenorphine allowed for the
administration of larger doses, which would
have a long duration of action. The tight
binding also makes it difficult for opioid
antagonists to displace buprenorphine.
However, since the opioid effect of respiratory
depression is relatively mild with
buprenorphine, it is safer than other opioid
full agonists such as methadone. The tightness
of binding is thought to be one of the possible
reasons for the low level of withdrawal
symptoms, associated with the abrupt
discontinuation of chronic administration of
buprenorphine, when compared with other
opioids. However, its partial agonist properties
may also be involved in this phenomenon. 
4.2 Pharmacokinetics
Pharmacokinetics may be defined as the study
of the time course of absorption, distribution,
metabolism and excretion of drugs. It is
essential to consider the pharmacokinetic
profile of buprenorphine, as this may have
potentially clinically relevant implications 
in the area of drug interactions. 
4.2.1 Absorption 
After oral administration, buprenorphine is
relatively ineffective because there is an
efficient first-pass metabolism by the liver.
However, it is reasonably well absorbed
sublingually – the absolute bioavailability of
buprenorphine from a sublingual solution dose
Review of Clinical Pharmacology
Chapter 4
H3CO
HO
HO C(CH3)3
O
C CH3
HCI
N CH2
in ethanol was recorded at approx 30% by
Mendelson et al (1997). This study, undertaken
in healthy volunteers, also noted equivalent
bioavailability for 3 and 5 minutes sublingual
exposure to the ethanol solution. It is
estimated that absorption from the oral route
is 15% of that from the sublingual route. 
Although most of the studies reported in the
Clinical Trials Section (see Chapter 5) used an
ethanol solution for sublingual administration,
buprenorphine has been formulated into a
tablet for sublingual use for commercial
presentation. Schuh and Johanson (1999)
compared plasma concentrations after doses
of 2, 4, 8mg buprenorphine solution and the
8mg tablet. Each dose was administered to 14
opioid dependent patients for a total of 7
days, at a time. Blood samples were collected
over the next 3 days, before changing to the
next dosage regimen. Although there was
considerable individual variability, the mean
plasma concentrations were significantly 
lower for the 8mg tablet than those of the
8mg solution at the 120 minute time point.
The plasma concentrations produced by the
8mg tablet were 55% of those produced by
the 8mg solution. Similar results were
reported by Nath et al (1999). Finally, workers
have noted that the buprenorphine tablet is
easily crushed and injected and therefore has
the potential for abuse (Mattick et al, 1998).
4.2.2 Metabolism 
(including drug interaction)
The metabolism of buprenorphine is shown 
in Figure 2. 
Patients prescribed buprenorphine are likely 
to receive other medications, therefore it is
important to consider the issue of drug
interactions. There are few data in the
literature documenting formal pharmacokinetic
studies with buprenorphine. However,
knowledge of its kinetic profile may help 
to identify potential drug interactions. 
The two main routes of metabolism include
glucuronidation to buprenorphine 3-0-
glucuronide (80-90%) and N-dealkylation to 
N-dealkyl buprenorphine (10-20%). Although
the N-dealkylation pathway represents less than
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Figure 2: Metabolism of buprenorphine
20% of the metabolism it is important to note
that this pathway is mediated by cytochrome
P450 3A4. As this enzyme is involved in the
oxidative metabolism of over 50% of the 
drugs used in humans the potential for drug
interactions is evident. The combination of
buprenorphine and benzodiazepines has
resulted in respiratory depression (see 
Chapter 6, Drug Safety). This results from 
a pharmacodynamic and possibly a
pharmacokinetic interaction. Therefore,
buprenorphine should be used with caution 
in the presence of benzodiazapines. Review 
of their kinetic profiles suggests that certain
benzodiazepines are more likely to interact 
e.g. lorazepam, temazepam and oxazepam 
and therefore these may be best avoided. 
In addition, caution is advised when co-
prescribing neuroleptics where the potential for
interaction may result from a pharmacodynamic
and/or pharmacokinetic mechanism. 
Drugs such as haloperidol, chlorpromazine,
pimozide and clozapine are metabolised by
similar enzymes mediating buprenorphine
metabolism i.e. cytochrome P450 3A4 and
glucuronyl transferase (GT). Potential
interactions may also result from combination
with some of the selective serotonin reuptake
inhibitors (SSRIs) such as fluoxetine (Prozac®)
and fluvoxamine (Faverin®), which inhibit
CYP3A4 and sertraline (Lustral®), which is
metabolised by this enzyme. Citalopram
(Cipramil®) and paroxetine (Seroxat®) are less
likely to interact, however all SSRIs may
potentiate the central nervous system
depressant effects of buprenorphine.
Some tricyclic antidepressants amitriptyline,
desipramine, imipramine and clomipramine 
are metabolised by CYP 3A4 and GT hence 
the potential for interaction. Nortriptyline and
dothiepin are less likely to result in a kinetic
interaction but all of these drugs have the
potential to enhance the central depressant
effects of buprenorphine through a
pharmacodynamic mechanism. Other agents
that enhance the central nervous system
depressant effects of buprenorphine include
other opioid derivatives, sedative H1 receptor
antagonists, clonidine and related substances.
Monoamine oxidase inhibitors (MAOIs) may
also exaggerate the effects of buprenorphine.
Injection drug use is the more common risk
factor for the acquisition of HIV infection in
Ireland, with drug users representing 42% of
the total HIV positive cohort (HIV/AIDS
Statistics, 1999). Drugs used in the treatment 
of HIV disease and associated opportunistic
infections may interact with buprenorphine.
With respect to anti-HIV drugs, the nucleoside
analogues are unlikely to interact with the
exception of zidovudine (AZT). As both drugs
are metabolised predominantly by
glucuronidation, buprenorphine could
potentially increase the toxicity of AZT by
inhibiting its metabolism (and vice versa). 
The potential interactions with the second group
of anti-HIV drugs – the non-nucleoside reverse
transcriptase inhibitors e.g. nevirapine, efavirenz
and delavirdine – are complex. Nevirapine and
efavirenz are potent enzyme inducers and might
be expected to increase buprenorphine
metabolism thereby reducing its efficacy.
Delavirdine may inhibit buprenorphine
metabolism and therefore enhance its toxicity.
The third group of anti-HIV drugs includes the
protease inhibitors ritonavir, saquinavir, indinavir,
nelfinavir and amprenavir. These drugs inhibit
CYP 3A4 and therefore would be expected to
increase buprenorphine levels. As ritonavir is a
potent enzyme inhibitor, affecting the function
of many isoenzymes, it should not be prescribed
with buprenorphine until more data are available.
Drugs used in the treatment of opportunistic
infections may also interact with
buprenorphine. The macrolide antibiotics
erythromycin and clarithromycin inhibit CYP
3A4 but azithromycin would not be expected
to inhibit this enzyme and therefore would 
be the drug of choice. Similarly, the azole
antifungal agents inhibit CYP 3A4 e.g.
ketoconazole, intraconazole and to a lesser
extent fluconazole. Enzyme inducing drugs 
will enhance buprenorphine metabolism and
therefore reduce its efficacy. Recognised
inducers are phenytoin, carbamezapine and
phenobarbitone (anticonvulsants) and the
antituberculous agent rifampicin. 
To date, there are no reports of a significant
interaction with cocaine, one of the agents
most frequently used by polydrug users in
association with opioids. This is likely due 
to the fact that cocaine is metabolised by
different enzymes i.e. hydrolysis by serum 
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and hepatic pseudocholinesterase (90%) and
hepatic N-demethylation. Ecstasy (MDMA) 
is metabolised by CYP 2D6, which is not
involved in buprenorphine metabolism. 
Acute alcohol intake may impair the
metabolism of buprenorphine, in addition to
the enhancement of the central depressant
effects, therefore acute alcoholism is a
contraindication, as is delirium tremors. 
The situation is further complicated by the
incidence of hepatitis C co-infection in this
patient population, which may be as high 
as 90% (Smyth et al 1995). The long-term
treatment of choice for hepatitis C involves
combination therapy with ribavirin and
interferon. Although formal interaction studies
have not been completed it is unlikely that a
significant interaction between these drugs
and buprenorphine would occur. 
Finally, the presence of liver disease may be
expected to alter buprenorphine kinetics. The
metabolism of morphine (also glucuronidated)
is altered significantly in the presence of
hepatic cirrhosis where clearance may be
reduced by 60%. Therefore caution is required
when prescribing buprenorphine in the
presence of liver disease. Frequent monitoring
of liver function tests is advisable in view of the
reported increase in AST and ALT following the
introduction of buprenorphine therapy. Severe
hepatic insufficiency is a contraindication to
buprenorphine use (see Chapter 6).
4.2.3 Elimination
The main pathways of elimination include biliary
excretion, hepatic glucuronidation and N-
dealkylation. Elimination also occurs via the
urine. In single dose studies, most of the dose (50
– 70%) was eliminated in the faeces over the first
4 days. Both unchanged drug and metabolites
were detected (Walter and Inturrisi, 1995).
4.3 Preclinical studies 
Buprenorphine has been evaluated in a
number of standard rodent assays, which
confirmed its dual agonist – antagonist
activity, characteristic of a partial agonist
(Rance, 1979). In terms of pharmacokinetic
evaluation, the oral bioavailability in the 
dog was low (mean 7.4%) but parenteral
administration gave better results – 
70% bioavailability after intramuscular
administration in the baboon (Walter and
Inturrisi, 1995). The sublingual route gave a
bioavailability of 30-50% of the dose (thought
to reflect the human situation) but was slower
compared to the parenteral routes.
Buprenorphine was widely distributed after
absorption (Heel et al, 1979). Brain levels were
higher than plasma levels at all time points in
the rat. Only unchanged buprenorphine was
present in the brain. In studies, in pregnant rats,
radioactivity readily reached the placenta
following oral parenteral dosing of radiolabelled
buprenorphine. It appeared to accumulate in the
foetal gastrointestinal human, thought to be due
to biliary excretion, in the absence of a
developed entero-hepatic circulation.
Excretion in the rat, dog and rhesus monkey
was primarily via the faeces, following biliary
excretion of conjugated unchanged drug and
metabolites. Small amounts were noted in 
the urine (Walter and Inturrisi, 1995). A study 
in rats, using radiolabelled buprenorphine
administered intramuscularly showed that
drug-related material was excreted in the milk
of rats and that concentrations of unchanged
buprenorphine in milk were at least equal to
that in plasma (Heel et al, 1979).
A series of animal toxicological studies was
undertaken with buprenorphine by the
manufacturer in the 1970s, when it was being
developed as an opioid analgesic temgesic®.
These included acute and chronic dose
administration studies, reproduction
toxicological studies and carcinogenicity studies.
The findings showed no major tissue or
biochemical toxicity after continuous
subcutaneous administration for periods of 
up to 6 months (SPC, 2001). However injection
site reactions were noted in many studies. It was
found to be non-carcinogenic in mice after 86
weeks of administration, in rats after 99 weeks of
administration at dosages of up to 2mg/kg/day.
(unpublished data – company report 1997). The
proposed sublingual dose range of
buprenorphine for the management of opioid
dependence is 2mg-32mg/day. This corresponds
to 0.03mg/kg-0.45mg/kg per day, based on a
70kg man. There was no apparent effect on
fertility and no teratogenicity in rats and rabbits
but there was a slightly increased risk of
parturition difficulties and increased neonatal
mortality at the 5mg/kg/day dosage (Heel et al,
1979) probably due to maternal toxicity.
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4.4 Summary and conclusions
Buprenorphine has been shown to be a partial
opioid agonist. Its metabolic pathway suggests
that there might be difficulties with drug
interactions either with co-prescribed
medications or co-administered illicit drugs.
The clinical relevance of this will be discussed
in the following sections. An extensive battery
of tests has been undertaken in several animal
species, evaluating the pharmacological and
toxicological profiles of buprenorphine. Many
of these were undertaken by the manufacturer
in support of its application to license
buprenorphine as an analgesic in the 1970s.
Results show that buprenorphine’s
pharmacodynamic and pharmacokinetic
profiles are consistent across animal species
and are similar to those seen in man. The
toxicological studies show an acceptable
margin of safety for use of buprenorphine 
in the management of opioid dependence
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5.1 Use of buprenorphine for
the management of opioid
withdrawal
Managed opioid withdrawal (detoxification) 
is thought to be an important component 
of an effective treatment system for opioid
dependency (Gowing et al, 2001). It is used to
bring about drug-free status within a period of
weeks/months. If used as a treatment entity in
its own right, it is associated with a high rate 
of relapse once the “withdrawal” period is
completed (Mattick & Hall, 1996). Therefore, it is
usually used as part of a treatment programme.
In those EU countries which have favoured drug-
free treatment (as opposed to substitution
treatment) programmes, detoxification is also
associated with psychosocial/rehabilitation
programmes (EMCDDA, 2001; Farrell et al, 2000).
It may also be used as a first step for other forms
of treatment or at the end of an extensive period
of substitution therapy (Gowing et al, 2001).
There are no standard/established
detoxification regimens and therefore review
of the literature provides diverse information
regarding medications used, regimens followed
and patient management. The largest body 
of data comes from a systematic review
undertaken by the Cochrane collaboration 
and published in 2001 (Gowing et al), which
assessed the effectiveness of short-term use
of buprenorphine in the management of the
acute phase of opioid withdrawal. As with 
all Cochrane reviews, a thorough search of
electronic databases, with subsequent retrieval
of all relevant references was undertaken. It is
not stated in the protocol what time limits
were placed on the search, but it is noted that 
the references encompass a time period from
1982 up to 1999.
Studies were considered for the meta-analysis if
(a) they were randomised or quasi-randomised
controlled clinical trials or prospective
controlled cohort studies, (b) they involved
administration of buprenorphine over a short
period (up to 10 days maximum) to ameliorate
the signs and symptoms of opioid withdrawal
and (c) they compared buprenorphine with
another form of treatment or placebo. 
It is important to mention that the cut-off
point of 10 days was selected as it was judged
by the reviewers to most accurately reflect
the typical duration of the acute phase of
opioid withdrawal. Studies, which were not
suitable for inclusion in the formal meta-
analysis, were also considered if they provided
information not available in the meta-analysis
studies (e.g. data on subgroups). The outcomes
to be measured in the meta-analysis were (1)
intensity of signs and symptoms and overall
withdrawal syndrome experienced, (2) duration
of treatment, (3) completion of withdrawal
and (4) nature and incidence of adverse
effects. Because it might be difficult to
differentiate between (1) and (4), the reviewers
defined adverse effects as those typical of
opioid withdrawal (such as vomiting and
diarrhoea) and incidents not typical
components of opioid withdrawal (such as
hypotension and dry mouth).
The review also aimed to look at the influence
of subgroups on the outcomes, the drug of
dependence, severity of dependence, polydrug
use, concurrent illness, effect of the treatment
setting and adjunctive treatment (such as
psychosocial counselling etc).
After an extensive search of the literature,
together with contact with researchers in the
particular area, a total of 22 reports covering
20 studies were identified. Five of the studies
met all of the inclusion criteria for systematic
review. Nine were excluded because they
entailed administration of buprenorphine for
more than 10 days (n=8) or provided limited
data on the participants (n=1). The remaining
studies were used to provide supplementary
data. The studies included in the systematic
review are summarised in Table 5.1
There was variability in the characteristics of
participants in the five included studies in
terms of numbers of injectors and
employment rates. Moreover, two of the
studies were judged to be subject to bias
(small numbers, possibility of attrition bias).
Review of Clinical Studies with buprenorphine 
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Table 5.1: Studies included in the Cochrane systematic review of “Buprenorphine for the 
management of Opioid withdrawal”, Gowing et al, 2001.
Legend for Table 5.1
RCT = Randomised Controlled Trial
db = Double Blind
BPN = Buprenorphine
Clon = Clonidine
Nalt = Naltrexone
S/L = Sublingual Administration
I/V = Intravenous Administration
I/M = Intramuscular Administration
Study Type Numbers Doses Comparator Result
Cheskin et RCT/db 25 recruited BPN S/L 2mg/ Clon 0.3mg/dose Lower withdrawal
al 1994 (18 in analysis). dose to a max to a max of 2.7mg symptoms & higher
All heroin users of 17mg over over 5 days completion rates
3 days for BPN
Janiri et al RCT/db 39 (13 per group) BPN 1/M Clon 0.3-0.9mg/ Withdrawal scores
1994 22 Meth users; 0.9mg days day X 6 days or better with BPN.
17 meth/heroin 1 + 2 and Lefetamine 60 – Completion rates
users then 0.45mg 240mg / day X equal for 
on day 3 + 6 days all groups
0.15mg on day 4
Nigam et al RCT 72 recruited BPN S/L 0.6 – Clon Subjective &
1993 (44 in analysis 1.2mg/day 0.3-0.9mg/ Objective 
– 22 per group). X 10 days day X 10 days withdrawal
90% heroin users. (3 divided doses) (3 divided doses) scales better
Rest opium users. with BPN. 65% v
No I/V users. 50% completion
rates BPN v Clon
O’Connor RCT/db 162 recruited BPN S/L 3mg / Clon Higher withdrawal
et al 1997 (53 BPN & then day X 3 days & 0.1 – 0.2 every scores for BPN on 
54 Clon + nalt; then Clon & 4 hours X days 1-4 but lower 
55 Clon). All Nalt 7 days + Nalt thereafter. 
heroin users 50mg on day 8; Completion 
Clon as above plus rates equal.
Nalt 12.5mg – 50mg
on days 1-3
Umbricht RCT 60 recruited BPN S/L 12mg Nalt given either Withdrawal scores 
et al 1999 (32 on BPN – day 1; 8mg day 2; in combination declined with BPN.
Nalt; 28 on BPN 4mg day 3; 2mg or after BPN Completion rates 
followed by Nalt). day 4 12.5 – 50mg per 76% v 56% BPN
Heroin users – day to day 8 + then Nalt 
only 30% injectors
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Heroin was the main opioid of abuse in four 
of the five studies (n=290). The other study
had participants withdrawing from methadone
(n=22) or methadone and heroin (n=17). A small
number of patients were opium smokers. The
inhalation route is thought to result in lower
levels of dependence (Strang et al, 1999).
Clonidine is an alpha-adrenergic blocking
agent, originally developed as an anti-
hypertensive treatment. It has also been
shown to be effective in suppressing the
opioid withdrawal syndrome (Gossop, 1988).
Four of the studies compared buprenorphine
with clonidine, but each study’s treatment
regimen was vastly different, in terms of
dosage and timing of buprenorphine and
clonidine and also in the manner of use of
concomitant medications. The fifth study
compared buprenorphine administered with 
2 different regimens of naltrexone. The 
studies differed greatly in terms of the way
“completion of withdrawal” was determined
and in the evaluation of withdrawal severity. 
In addition, different preparations and routes
of administration of buprenorphine were used
in the various studies. 
The results showed that where buprenorphine
was compared with clonidine, the results
tended to favour buprenorphine in terms 
of alleviating the symptoms of opioid
withdrawal. However, because varying
treatment regimens were used in all studies, 
an overall evaluation of dose response and
relative efficacy was not possible. Information
on the usefulness of buprenorphine in
participants withdrawing from methadone was
sparse but suggested that it was as effective as
clonidine. It is important to note that the dose
of methadone had been reduced to 10mg/day
before entry into the withdrawal programme. 
One of the supplementary studies (Banys 
et al, 1994) suggested that there might be 
racial differences in the metabolism of opioids,
which might account for differences in the
efficacy of buprenorphine but the numbers
were small (n=15). Although the study from
Bickel et al (1988) was described as a
detoxification study, it involved administration
of buprenorphine or methadone for 7 weeks 
in a randomised controlled double blind trial
and therefore was classified as one of the
supplementary studies. The results in this study
were similar, in terms of retention in treatment
and illicit opioid use for buprenorphine 2mg 
or methadone 30mg given daily. But
buprenorphine was less able to attenuate the
effects of opioid challenge (hydromorphine
6mg administered intramuscularly). This 
was the first randomised controlled trial to
compare buprenorphine and methadone in
opioid dependent patients.
Because of the wide variability in the study
limits between the five included studies, it
was not considered appropriate to undertake
formal meta-analysis in the review. However,
the reviewers’ overall conclusion was that
short-term use of buprenorphine appears 
to have potential as an approach in the
management of withdrawal from opioid
dependency. It was not possible to provide
recommendations on an appropriate
treatment protocol (in terms of dosage 
or duration of treatment).
Clonidine, used at the dosage needed to
suppress opioid withdrawal syndrome is
associated with a number of adverse effects
(such as hypotension and sedation) and
therefore patients require close medical
supervision (Ward el al, 1998). Lofexidine is 
a structural analogue of clonidine but with 
less side effects and it has been used widely 
in the UK for opioid detoxification since it was
authorised in 1992. An open label study was
published recently (White et al, 2001), which
compared buprenorphine with lofexidine in 
the management of withdrawal in a community
setting. The results showed that subjects
receiving buprenorphine were more likely to
complete detoxification and had a less severe
withdrawal syndrome than lofexidine. The
efficacy of buprenorphine was dose-related.
Although this study was not randomised and
involved retrospectively reviewed subjects as
well as prospectively followed subjects, the
result supports the use of buprenorphine in
the management of opioid withdrawal. The
design of the study precluded conclusions
regarding relative efficacy, however the
investigators found that matching the dose of
buprenorphine to the subject’s daily opioid use
prior to treatment resulted in a less severe
withdrawal syndrome and greater chance of
completion of treatment. 
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Summary 
Although managed withdrawal has been
recognised as an important treatment option 
in the management of opiate dependency for
many years, no established treatment regimens
exist to date. A systematic review of the use of
buprenorphine for the management of opioid
withdrawal has recently been undertaken by
the Cochrane Collaboration group. The studies
identified were found to be too heterogeneous
to allow formal meta-analysis to be
undertaken. However buprenorphine was
evaluated using a number of dosage regimens,
and was shown to be at least as effective as
clonidine (the treatment option most widely
reported) in terms of reduction of severity 
of withdrawal syndrome and completion of
withdrawal. The authors concluded that
“buprenorphine has potential as a medication
to ameliorate the signs and symptoms of
withdrawal from heroin and possibly
methadone” (Gowing et al, 2001). There was
insufficient information for the authors to be
able to recommend the appropriate dosage
regimen, but the importance of titration of the
dose to the individual subject was highlighted
in some reports.
5.2 Use of buprenorphine as
substitution therapy in the
management of opiate
dependency
Examination of all data sources (outlined in
Chapter 3) has recovered a large body of data
pertaining to the use of buprenorphine in the
treatment of opioid dependence. In addition,
the search identified that the Cochrane
Collaboration is currently undertaking a
systematic review of the use of buprenorphine
maintenance (versus placebo or methadone)
for opioid dependence (Mattick et al, 2001).
This is due to be published shortly but the
published protocol was taken into account
when undertaking the current review.
Problems have been identified with these 
data and these are discussed below. 
Evaluation of the clinical trials has been
divided into separate sections – randomised
controlled trials (with or without an active
comparator), sub-group analysis including use
in pregnancy, dose-ranging studies, and non-
randomised open label studies.
5.2.1 Randomised controlled
trials with an active
comparator
A summary of all identified randomised
controlled trials of buprenorphine versus an
active comparator is given in tabular form in
Appendix III.
Two meta-analyses have been identified from
the literature (Barnett et al, 2001 and West et
al, 2000), which compare buprenorphine with
methadone. There is a good deal of overlap
between the two (5 randomised controlled
comparative studies from the 1990s are
common to both), but Barnett et al (2001)
appears to be the more statistically sound. A
brief summary of the evaluation of these
meta-analyses follows:
West et al (2000) provide a meta-analysis of 
9 separate trials comparing buprenorphine 
to methadone. This meta-analysis is
considered inferior to that by Barnett et al
(2001) as it includes very different types of
studies, and does not use the original data but
attempts to extract the information from 
the published articles (weaker methodology).
For these reasons only the meta-analysis of
Barnett et al is considered in detail.
Barnett et al (2001) provides a comprehensive
meta-analysis of four of the five randomised
trials comparing buprenorphine and
methadone published up to 1998 (Table 5.2),
using “high dose” buprenorphine i.e. daily
doses of at least 6mg per day (range 6-12mg
per day), and “high dose” methadone i.e.
average daily doses of 60mg per day (range
50-80mg per day). Patients in the included
studies are followed up for 16-24 weeks, and
two summary statistics are extracted from
each study and combined in the meta-analysis.
These are:
a) Proportion of positive urinalysis tests 
(out of all possible tests). Missing tests are
handled in one of two ways (i) treated as
positive and (ii) excluded from the analysis.
b) Hazard ratio (or relative risk of
discontinuation in buprenorphine 
group compared with methadone 
group) calculated using Cox proportional
hazards model. 
Overall, the authors found a significant
difference, with an average 8.3% (p=0.002)
more positive urinalysis tests with
buprenorphine than methadone. Although
statistically significant, the result is not of
particular clinical significance or importance.
The overall rate of discontinuation was 1.26
times greater in the buprenorphine group 
than in the methadone group (p=0.019). This
reduces to 1.17 (p=0.087) if one study, based 
On a lower dose of buprenorphine, is
excluded. In a sub meta-analysis of three trials
(Barnett et al), found that those on
buprenorphine have 8.4% (95% CI 1.2-5.6%)
fewer positive urinalysis tests and lower rate of
discontinuation than low dose methadone.
Some of the included studies reported other
secondary outcomes, such as self-reports of
illicit drug use, withdrawal symptoms, but as
these were not reported in all studies they are
not considered further in the meta-analysis.
Since this analysis was performed, a further 4
randomised trials have been identified. Petitjean
et al (2001) compared the safety and efficacy 
of sublingual buprenorphine tablets with oral
methadone in a population (n=58) of opioid-
dependent individuals in a double blind,
randomised, six-week trial using a flexible
dosing procedure. This study reported better
retention rates for methadone, although the
high attrition rate with buprenorphine occurred
in the induction phase and therefore was
thought to be due to inadequate induction
doses. There was no difference between the
groups in terms of positive urine samples,
withdrawal symptoms or concomitant ingestion
of cocaine. 
Pani et al (2000) enrolled 72 subjects from 
9 treatment units in a randomised controlled
double blind study to receive either sublingual
buprenorphine (8mg/day) or oral methadone
(60mg/day) for 6 months. There was no
significant difference between the groups at
the end of the study. A non-significant trend
in favour of methadone was noted in respect
of retention in the study, but the investigators
reported that the subjects on buprenorphine
who dropped out differed significantly from
those who stayed, in terms of a higher level 
of psychopathological symptoms and a lower
level of psychosocial functioning. 
Johnson et al (2000) compared LAAM
(75–115mg), buprenorphine (16–32mg) and high-
dose/low dose methadone (60–100mg/20mg
respectively) in a 17-week randomised study 
of 220 subjects (55 per group). Methadone was
administered daily and the other medications
were administered thrice weekly. Results
showed that LAAM, buprenorphine and high-
dose methadone were superior to low-dose
methadone in terms of treatment retention,
urine toxicology and withdrawal
symptomatology. It also showed that thrice
weekly administration of buprenorphine was
comparable with daily methadone treatment
(see also 5.2.5).
Finally, Fischer et al (1999) randomised subjects
to receive either buprenorphine or methadone
on a daily basis in an open comparative study
for a period of 24 weeks. A total of 60 subjects
with opioid dependence were enrolled. 
The results showed that retention rates were
significantly better in the methadone group
but that the buprenorphine subjects who
completed the treatment had significantly
lower rates of illicit opioid drug usage. 
This study is of interest in that it is the first
comparative study to use the sublingual
buprenorphine tablets (as opposed to the
ethanol solution). The mean daily dose of
buprenorphine used was 7.5mg (compared 
with 63mg of methadone). This study was
included in the meta-analysis from West et al.
After detailed evaluation of these additional
studies, the first two were not considered
suitable for inclusion in a meta-analysis.
Petitjean et al studied the subjects for a
period of 6 weeks only, and this was not
considered long enough to examine retention
on treatment, while Pani et al used a fixed
dosing rather than flexible dosing regimen
used in the other studies. For the remaining
studies (Fischer et al, Johnson et al), the main
authors were contacted in relation to the use
of their original data/statistics. This was to
enable the results from their studies to be
incorporated into a further meta-analysis,
thereby updating the analysis of Barnett et al
(2001) (see Table 5.2 below). The same
statistical methods are used as Barnett et al
(described in Appendix I) to update the
analysis and these are based on weighting the
primary outcome measures from each study
by 1/variance of the outcome measure. 
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Data from both authors (Dr Fischer and Prof
Johnson) were obtained and included in a
further meta-analysis of all 6 studies. A
summary of the findings from each of the
studies by Fischer et al (1999) and Johnson et 
al (2000) are presented in Table 5.3 below. The
subjects’ mean proportion positive urinalysis for
the study by Fischer et al is slightly higher than
that from the other studies, and this is because
all subjects had to have positive urinalysis in the
week 1 induction period, which was included in
the proportion positive urinalysis (~5-10% higher
proportion because of this). As the present
analysis focuses on the difference between the
groups, this was not considered to be a
problem. The retention rate for buprenorphine
in the study by Fischer et al is considerably
worse than for methadone, as indicated by the
large relative hazard ratio of 2.58 (i.e. those on
buprenorphine 2.58 times more likely not to 
be retained in treatment than the methadone
group). This was explained to some extent 
by the slow induction and low upper dose 
of 8mg buprenorphine (tablet) during the first
few weeks of the study, as well as reported
‘undifferentiated dysphoria’ and ‘a state of
clarity’ during the induction phase on
buprenorphine, and more severe withdrawal
symptoms observed with buprenorphine. The
bioavailability of the tablet formulation of
buprenorphine has been reported to be half
that of the ethanol formulation (Nath et al
1999; see also Chapter 4)
When the data from these studies were added
to those from the 4 main studies already
reported in Barnett et al (i.e. excluding Kosten
et al), significant heterogeneity between
studies was observed only in the case of the
retention in treatment outcome (Cochrane’s
Q=20.07, p<0.001), attributed to Fischer et al
for the reasons given above. The final meta-
analysis of the 6 studies for positive urinalysis
are shown in Table 5.4a below. The results
indicate that those on buprenorphine had 
8% more positive urinalysis than those on
methadone. Although statistically significant
(p<0.05), the result was not considered
clinically significant. 
The results from combining the 5 studies 
(i.e. excluding Kosten et al and Fischer et al) 
in relation to non-retention on treatment are
given in Table 5.4b. They show that those on
buprenorphine are 1.23 times more likely not 
to be retained on treatment than those on
methadone, but this result is not statistically
significant, and therefore it is concluded there
is no difference between groups in retention
rates. This is further illustrated, in Table 5.5,
which outlines the completion rates in each 
of the six studies. Only one study (Fischer 
et al, which was described above and was 
not included in the retention analysis) showed
significant differences between the
buprenorphine and high dose methadone.
Buprenorphine at 8mg/day was shown to have
significantly higher retention rates than lower
dose methadone (20-35mg) in Johnson et al
(1992), but no statistically significant differences
were noted between high dose buprenorphine
(12mg) and low dose methadone (25mg) in the
Schottenfeld et al (1997) study.
There is wide variability between the designs 
of the studies, doses of methadone and
buprenorphine and types of non-pharmacological
interventions and subjects in the various studies
described, which means the results need to be
interpreted with some caution. 
Since the data lock point, another meta
analysis has been identified (Farré et al, 2002).
This compared the efficacy of methadone with
that of buprenorphine and LAAM. The results
showed that there was no significant difference
between high dose buprenorphine (≥ 8mg/day)
and high dose methadone (≥ 60mg/day) for
both treatment retention and illicit opiate use.
Methadone was more effective than lower
dose buprenorphine (<8mg/day).
5.2.2 Placebo studies
Only one study has been identified here. 
This was undertaken to satisfy FDA guidelines
on evaluations of new medicines and was part
of a larger study undertaken by the research
group (Johnson et al, 1995). It was a double
blind randomised study, which involved 150
subjects who were randomised to receive 2
different dosage regimens of buprenorphine 
or placebo for 14 days. After day 6, it was
possible to change to an alternative group.
Participants also received daily one-to-one
counselling. The results showed that actively
treated patients scored significantly better on
all outcomes (treatment retention, urinalysis,
withdrawal symptoms) than the placebo
group, but there was no difference between
the 2 dosage groups of buprenorphine.
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Study Methadone Buprenorphine Study Difference 95% 
dose (mg/day) dose (mg/day) numbers in mean  Confidence
proportion positive interval
urinalysis
Johnson (1992) 60 8 107 -0.022 -0.142, 0.097
Strain (1994) 50 8 164 0.051 -0.044, 0.146
Schottenfeld (1997) 65 12 57 0.155 0.001, 0.310
Ling (1996) 80 8 150 0.169 0.066, 0.273
Kosten (1993) 65 6 62 0.244 0.085, 0.404
Summary based Fails 
on all 5 studies heterogeneity
test
Summary based 0.083* 0.027, 0.140
on excluding Kosten
Table 5.2: Summary of meta-analysis by Barnett et al (2001)
Fischer 63mg 7.5mg 24 60 0.734 0.677 0.057 -0.096, 0.210 2.58 1.21, 4.92
(1999) (mean) (mean) weeks
tablet form
Johnson 60-100 mg 16-32mg 17 110 0.667 0.613 0.054 -0.069, 0.177 1.71 0.89, 3.28
(2000) (thrice weeks
weekly)
Study Methadone BPN Study Number BPN Methadone Difference 95% Relative 95%
dose dose length of Confidence Hazard Confidence
subjects Interval for ratio Interval
the difference
Study characteristics Subjects mean proportion 
positive urinalysis for opiates 
Non retention in 
treatment
buprenorphine
vs methadone
Table 5.3: Summary of study characteristics and results 
from Fischer et al (1999) and Johnson et al (2000)
Difference in proportion 0.076 (p<0.05) 0.03, 0.12 Q=7.24, 5df
positive urinalysis between P=0.203
buprenorphine and methadone
Difference Confidence Test for 
(p-value) Interval homogeniety
Table 5.4a: Final meta-analysis of positive urinalysis results from 6 studies
Table 5.4b: Final meta-analysis of non-retention in treatment 
(relative hazard ratio) from 5 studies (excluding Fischer et al)
Non-retention of 1.23 (p=0.07) 0.98, 1.53 Q=5.5, 4df
buprenorphine vs P=0.24
methadone
Relative Confidence Test for 
Hazard ratio Interval homogeniety
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5.2.3 Subgroups of responders 
to buprenorphine
Few randomised or non-randomised studies
have examined specific sub-groups of
responders to buprenorphine treatment. 
A summary of those that have is given in 
Table 5.6 below.
One study already included in the meta-
analysis of randomised controlled trials (above)
is that of Schottenfeld et al (1998). Here the
authors found significantly better rates of
abstinence from opioids, and better overall
retention rates in women compared with men,
and this was particularly the case for those on
buprenorphine 4mg. The authors attribute the
gender differences to possible differences in
central opioid neuronal pathways, with findings
of increased mu receptor density in women,
although they also comment on the limited
power of the study due to the small numbers
of women studied. Subjects with a history of
sedative dependency had lower attrition from
treatment in both buprenorphine groups (4mg
and 12mg) compared with the methadone
65mg group. 
Others (Pani et al, 2000 and Resnick et al, 1991)
found that higher levels of psychosocial
functioning resulted in better adherence and
response to buprenorphine than those with
lower psychosocial functioning, suggesting
that those with higher psychosocial
functioning would be more suitable for
buprenorphine treatment. Kosten et al (1990)
found that the effect of buprenorphine on
signs of depression was short-lived, and that
the rate of dropout on buprenorphine was
marginally worse (p=0.06) in the depressed
compared with non-depressed subjects during
follow-up. Schottenfeld et al (1998) found no
association between depression and outcomes
of treatment (retention or illicit opioid use) in
those on buprenorphine and methadone. 
Laqueille et al (2001), in an observational 
study, followed 73 subjects on buprenorphine
(mean dose 8.5mg/day) for 3 months and
assessed response to treatment as remaining in
the study and having more than 75% negative
urine tests over the last month. They observed
better response in those with: opiate addition
less than 10 years, a high score on the Addiction
Severity Index, an absence of depression, and a
Fischer 1999 BPN 7.5mg (29) tablet 38%
(24 weeks) Meth 63mg (31) 71%*
Johnson et al 2000 BPN 16-32mg (55) 58%
(17 weeks) Meth 60-100mg (55) 73%
Schottenfeld 1997 BPN 12mg (29) 55.2%
(24 weeks) BPN 4mg (29) 34.2%
Meth 65mg (28) 64.3%
Meth 25mg (30) 46.7%
Strain et al 1994 % days’ attend clinic
(26 weeks ) BPN 8mg up to 16mg (mean 11.6mg) (24) 81%
Meth 50 up to 90mg (mean 66.6mg) (27) 88%
Ling et al 1996 At 26 weeks At 52 weeks
(26 weeks) BPN 8mg (75) 35% 20%
Meth 80mg (75) 52% 31%
Johnson 1992 17 weeks 25 weeks
(17 weeks + 8 week BPN 8mg (53) 42%Ö 30%Ö
detoxification) Meth 60mg (54) 32% 20% &
Meth 20mg (55) 20%Ö 6%Ö &
Study (duration) Dose (number of subjects) Overall % retention in study
Study duration Follow-up
Table 5.5: Completion rates by dose of buprenorphine and methadone 
in randomised trials included in the meta analysis
* significantly different (p<0.05) – see text for details
Ö & significantly different (p<0.05) from one another (within the same study)
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Study Subjects Subgroups-findings
Schottenfeld et al (1998) RCT – buprenorphine (4 or 12mg) Found a significant gender effect i.e.
versus methadone (20 or 65mg) better rates of abstinence of opioid
to assess the effect of gender use in women compared with men; 
and psychopathology and within the 4mg buprenorphine group
interaction with treatment. females also had better retention,
80 male : 36 Female and lifetime sedative use was also 
associated with better retention. No 
effect of depressive state on outcome.
Eder et al (1998) RCT – 16 on buprenorphine Buprenorphine appeared more 
(free dosing to a max 8mg); effective in the more motivated
18 on methadone (free dosing subjects and authors suggest 
no upper limit) further investigation here.
Pani et al (2000) RCT – 72 patients on Patients dropping out in the 
buprenorphine (8mg) or buprenorphine group differed 
methadone (60mg) followed significantly in their levels of 
up for 6 months psychosocial symptoms (serious 
symptoms of depression) from those
not dropping out. Predictors of good 
adherence were good psychic state 
and psychosocial adjustment
Ahmadi (2001) 330 subjects randomised Addicts previously using <2mg opium
to 3 doses of buprenorphine daily had better outcomes on
(110 in each) buprenorphine.
Johnson et al (1995) Placebo controlled trial Male subjects receiving 
versus buprenorphine buprenorphine had significantly fewer
positive urine tests during days 3-7
compared with placebo than females 
(but small numbers in this group). 
Suggest early effectiveness may be 
gender-specific.
Resnick et al (1991) 16 heroin dependent subjects Levels of psychosocial functioning 
followed for 26-32 months and global assessment of functioning 
with buprenorphine (non- were significantly higher for those 
randomised). Subjects asked responding to buprenorphine
to rate psychosocial compared with those not responding
functioning at baseline and (i.e. relapsed to heroin).
follow-up.
Laqueille et al (2001) Observational study Better response in those with: opiate
73 subjects on BPN addiction <10yrs; high score on ASI;
(mean dose 8.5mg/day) absence of depression; low 
for 3 months disinhibition rate (Zukerman scale)
Table 5.6: Sub-group analysis of randomised and non-randomised studies
RCT = Randomised controlled trial
ASI = Addiction severity Index
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low rate of disinhibition (Zukerman’s scale). The
dose of buprenorphine did not affect the
response.
In summary, the only sub-group which appears
to perform best on buprenorphine and for
which the results are replicated in more than
one study is the group of subjects that have
higher baseline levels of psychosocial
functioning and global functioning, and less
depressive illness. The effect of gender on the
response to buprenorphine was found in only
one study (Schottenfeld et al, 1998) and
requires further validation in other studies.
5.2.4 Use in pregnancy
The published literature contains a series of
case reports in which buprenorphine was used
during pregnancy (Johnson et al, 2001). These
retrospective reports involved women who
became pregnant while on buprenorphine
therapy and showed no particular problems
during pregnancy for the mother, with a
neonatal abstinence syndrome (NAS) in the
infant of mild-moderate intensity (Reisinger
1997, Eder et al, 2001).
Jernite et al (1999) analysed the cases of 24
opioid-dependent pregnant women (and their
offspring) who were treated with buprenorphine
during pregnancy. Of these, 13 were reviewed
retrospectively while 11 were followed
prospectively and actively managed throughout
pregnancy (medical and social support). The
results showed that the prospectively followed
group had much better outcomes, in terms of
prematurity, foetal growth retardation and acute
foetal distress. In addition, these women were
more likely to bring their infants home (90.9% vs.
69% of retrospective group). However there was
no difference in the level of NAS between the 
2 groups (63% vs. 69%). This highlighted the need
for total management of the opioid dependent
subject, in addition to substitution treatment,
during pregnancy.
A study, undertaken by Marquet et al (1997)
measured the levels of buprenorphine and 
the metabolite norbuprenorphine, around 
the time of birth, in the serum of a mother
(maintained on buprenorphine throughout
pregnancy) and compared them with those
found in the serum, urine and meconium of
the infant. Levels of buprenorphine were 6
times higher in the infant’s serum compared
with the mother, with correspondingly low
levels of the metabolite norbuprenorphine,
probably due to immature hepatic metabolism
in the infant. However, the infant experienced
a mild NAS only, which did not require
pharmacological intervention. Moreover, the
infant was breast-fed for 6 weeks with no ill
effect. The authors suggested that these
findings supported the safety of
buprenorphine during pregnancy.
Rohrmeister and workers (2001) enrolled all
infants, born in the university hospital of
Vienna to opioid-dependent mothers over a 
4-year period (March 1995 to September 1999).
A total of 88 infants were included with a
median gestational age of 39 weeks. Overall,
72% had to be treated for NAS, but the
incidence and duration of NAS with
buprenorphine treatment was significantly
lower than with other groups – 19% of the
buprenorphine group of infants required
treatment, compared with 76% of the
methadone group and 93% of the slow-release
morphine group. This study further supported
the use of buprenorphine during pregnancy. 
Two open-label studies have been undertaken
in pregnant opioid-dependent women. Fischer
and workers (1998; 2000) undertook an open-
label study evaluating a flexible buprenorphine-
dosing regimen in opioid-dependent pregnant
women. A total of 15 women were enrolled –
14 were receiving either methadone or slow-
release morphine maintenance treatment 
and one was on “street heroin” at enrolment.
They received a mean of 8.4mg/day of
buprenorphine and were entered into the
existing pregnancy and drug addiction
programme in the hospital. 
All were delivered of healthy infants. NAS was
mild in 4 (27%), moderate (requiring treatment)
in 3 (20%) and absent in 9 (53%) infants. There
was no correlation between the mother’s dose
of buprenorphine and risk of NAS.
The second open label study involved 3
opioid-dependent pregnant women in the
USA (Johnson et al, 2001). All were admitted 
to a hospital based specialist treatment
programme for pregnant drug-dependent
women. Only one had been treated previously
for opioid dependence. The women
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completed induction successfully over 
3 days and were maintained on doses of
buprenorphine of between 8 and 12mg/day
until delivery. Urinalysis was negative for
opioids on all occasions with one exception. 
All 3 women were delivered of healthy infants.
Symptoms of mild NAS were reported in all
infants. These peaked at 72 hours and returned
to pre 12-hour levels by 120 hours. None of the
infants required pharmacological intervention
for withdrawal.
Although these two studies were limited in
terms of design and numbers and give details
on the infants around the time of birth, the
results support the usefulness of
buprenorphine during pregnancy and its 
safety in terms of reduced NAS for the infant.
5.2.5 Dose ranging studies with
buprenorphine
The literature search has retrieved several
reports of studies, which investigated various
dosing schedules for buprenorphine. These
studies are too heterogeneous to enable a
formal meta-analysis to be undertaken.
Therefore, they will be systematically
reviewed on an individual basis in this section.
Studies identified may be divided into those
which sought to confirm the optimum daily
dose and those which evaluated the efficacy
of various less than daily dosing regimens.
Daily administration studies
A large multicentre study was undertaken 
by Ling et al (1998) to evaluate the safety 
and efficacy of an 8mg/day dosage of
buprenorphine, using a 1mg/day dose as
comparator. It was undertaken in co-operation
with the National Institute on Drug Abuse
(NIDA) and was intended to provide pivotal
information for a new drug application (NDA) to
the Food and Drug Administration (FDA), in the
USA. Therefore, it was designed according to
FDA guidelines. It was a randomised clinical trial
where the 1mg/day dose was adopted to serve
as placebo. It was double blind in design and
lasted for 16 weeks. Two other dose groups were
included – 4mg/day and 16mg/day – but the
results from these dose groups were evaluated
as secondary outcomes for statistical reasons.
Doses were administered under supervision
every day for the duration of the study. Urines
were collected three times weekly and analysed
for opiates and cocaine. Subjects enrolled in the
study were offered a 1 hour weekly counselling
session, in addition to daily attendance at the
clinic. Outcomes evaluated were (1) treatment
retention time in the study, (2) urine toxicology,
(3) self-reports of craving and global severity and
(4) severity ratings by the research team. 
A total of 736 subjects were enrolled at 12
specialist outpatient clinics. Approximately
180 were randomised to each treatment group.
Overall, 51% completed the study. Results for
the treatment retention for the 8mg and 16mg
groups were statistically significantly better
(p<0.05) than for the 1mg group (52% and 61%
versus 40%).
The results showed a consistently better
response for each outcome measure than 
the dose below it, although these differences
did not always reach statistical significance.
Urine toxicology results were significantly
better for the 8mg group than those for the
1mg group for urine toxicology (32.9% versus
18.5% negative for opiates). The investigators
evaluated the total number of negative urines
contributed by each patient as another
measure of treatment effectiveness (TES) and
found that the 1mg group was significantly
worse then the other dosage groups on this
score (5.6, 9.6, 10.3 and 13.9 for 1, 4, 8 and 16mg
respectively) where 48 is the maximum score
i.e. maximum number of urines collected.
Significantly higher craving scores occurred in
the 1mg group compared with the 8mg group
up to week 12 only. As might be expected, 
the craving scores in the 1mg completer group
were significantly worse than the 8mg and
16mg groups until week 8 only, after which the
difference was not statistically significant. Staff
ratings for the 8mg group were significantly
better than for the 1mg group throughout the
study, but patient self-ratings for these groups
only showed a significant difference in favour
of the 8mg dose at week 4.
This was not designed as a dose-response study
but the results showed an apparent monotonic
relationship between dosage and each outcome
measure. The study confirmed that 8mg was
statistically superior to 1mg for all outcomes
measured and therefore confirmed that
buprenorphine showed efficacy in the
management of opioid-dependent patients at
this dose. However, the low scores on the TES
and the low retention rates suggested that
further work was needed to define the
optimum dose for use in clinical practice.
Less than daily dosing
The need for daily administration of methadone
has been reported as a limitation to the
successful management of some heroin addicts
because (1) there are problems of compliance
with daily attendance and (2) daily attendance
reduces the numbers of patients that can be
treated. Buprenorphine’s profile of high affinity
binding to opioid receptors, (see Chapter 4)
coupled with pseudo irreversible binding, implies
a potential for a reduction in the frequency of
dosing (e.g. alternate day/every third day). 
Alternate day dosing
Several pilot studies, looking for the optimal
dosing regimen have been reported. Fudala
and workers (1990) evaluated a dose of 8mg 
of buprenorphine given either daily (n=9) or
every second day (n=10). Subjects were all
opioid-dependent and were initially stabilised
on 8mg for 18 days. Results showed that
alternate-day dosing was tolerated by the
group but that they consistently reported 
a greater urge for opioid use and higher
dysphoria scores on the placebo days. From
day 37 to day 52, all subjects were put on
placebo. No withdrawal signs were detected
using the standard Himmelsbach scale but 
the subjects complained of mild to moderate
opioid withdrawal symptoms lasting for up to
10 days. This preliminary study suggested that
alternate day dosing was possible but that
daily dosing provided greater control.
In a study undertaken in the USA in 1993
(Resnick et al) 31 opioid-dependent patients
who were maintained on doses of 4-16mg/day
for several months were given double their
daily dose every 2 days and evaluated for
withdrawal symptoms. The majority of
patients experienced no symptoms after 
the alteration in dosing schedule although
“restlessness and anergia” were noted in some
at the end of the interval period. The dosage
regimen was subsequently increased to triple
the daily dose every third day and, on follow-
up, 29 patients were maintained, heroin-free,
on this regimen. Patients expressed
satisfaction for the reduced clinic attendance
associated with this schedule. 
In a similar study, Amass and workers (1994)
compared daily versus alternate day
buprenorphine administration in 13 opioid-
dependent subjects who were stabilised (over
a period of 2 weeks) on either 2mg/70kg/day
(n=2), 4mg/70kg/day (n=6) or 8mg/70kg/day
(n=5). All medications were administered under
double-blind conditions, using a flavour
solution to mask the test dose. From day 14
onwards subjects were randomly assigned to
receive their maintenance dose either daily or
every second day (double dose) for 3 weeks,
after which they were eligible to enter a
crossover phase for the next 3 weeks. No
difference was noted between the groups in
terms of treatment retention, positive
urinalysis or subjective ratings (self and staff
ratings). There was a difference in the
subjective “agonist effect” ratings when the
treatment and placebo days were compared
for the first 3 week cycle, which was not seen
in the second cross-over phase. However, the
treatment schedule was well tolerated by the
group with 77% completion rates.
Although these studies involved small numbers
of subjects, the results suggest that less than
daily administration of buprenorphine may be
possible from a safety and efficacy point of view
and could lead to greater patient compliance.
However, these findings need to replicated using
much greater numbers of subjects.
Thrice weekly dosing
Chawarski (1999) undertook a double-blind
trial in a group of 10 opioid dependent
subjects. The study used a within-subject
design with three different thrice-weekly
dosing schedules of buprenorphine
administered sublingually, under supervision,
on Fridays, Sundays and Tuesdays. This dosing
period was preceded by a week of induction
(daily dosing) and followed by one week of
daily administration at the end of the study.
The different schedules were randomly
assigned, with each schedule lasting 3 weeks.
The same random allocation was repeated in
each patient, for a total of 18 weeks.
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Doses administered were as follows 
Daily dose – 16mg/70kg. Thrice weekly
Regimen A – 16mg;16mg;32mg/70kg; 
Regimen B – 22mg;22mg;40mg/70kg; 
Regimen C – 34mg;34mg;44mg/70kg. 
Each dose was based on bodyweight (70kg)
and therefore it was adjusted on an individual
basis. Subjects were evaluated by means of
urinalysis, self-reports and staff reports of
opiate withdrawal symptoms. In addition,
plasma samples were collected during the
second week of each thrice weekly regimen at
24, 38 and 72 hours post dose and at 24 hours
after daily administration (on 3 occasions).
Only one patient dropped out of the study 
(at 13 weeks). The number of urine samples
which was positive for opiates decreased 
from baseline, but there was no indication that
higher doses were more effective. Both
patient and staff scores showed low levels 
of withdrawal symptoms in each dosage group
(no significant difference).
Plasma levels showed wide intra-patient
variability but in general higher doses of
buprenorphine resulted in significantly higher
overall plasma concentrations. The plasma
levels at 74 hours after the higher thrice-
weekly regimen were comparable to the 
24-hour level seen with the 16mg/70kg daily,
supporting the feasibility of thrice-weekly
buprenorphine for maintenance treatment.
Two recently published studies (Schottenfeld
et al, 2000; de los Cobos et al, 2000)
compared the efficacy of daily versus thrice
weekly administration of buprenorphine in 
the management of opioid dependence. 
Both were randomised controlled double
blind trials. Schottenfeld enrolled 97 patients
(of whom 92 completed the 3 day induction
period) who were randomised to receive
buprenorphine at a total weekly dose of
112mg/70kg by either daily or thrice weekly
dosing for 12 weeks, in an ethanol-based
formulation.
Results showed treatment retention rates of 71%
and 77% (daily v thrice weekly). Concomitant
heroin use decreased significantly in each
group, as evidenced by a reduction of
approximately 50% in the number of opiate
positive urines and a decrease in the number
of self-reported days of heroin use per week.
Furthermore patients on thrice-weekly dosing
did not report increased craving or illicit drug
use during the “placebo” days. There was no
difference in the pattern of reported side
effects between the groups. 
The study was undertaken in the USA, where
cocaine abuse is a major problem. It noted 
an increase in the use of cocaine over the 
12 weeks of study. This was judged to be
important as cocaine use was an exclusion
criterion and 70/92 baseline urines had tested
negative. The authors suggested that this
would need further evaluation.
The overall conclusions were that the study
supported the clinical efficacy of thrice
weekly dosing.
In contrast, the second study (de los Cobos,
2000) randomly assigned 60 opioid dependent
subjects to receive a total 56mg
buprenorphine per week, administered either
daily or thrice weekly. Treatment was started
after an inpatient induction phase.
Buprenorphine tablets were used in this study.
Results showed similar retention rates of 63%
and 70% for daily and thrice weekly dosing
respectively. However illicit opiate use was
greater in the thrice-weekly dose group and
this became significant from week 3 onwards
with only 13.3% of the thrice-weekly dose
group achieving abstinence from opioids for 
at least 4 weeks, compared with 36.6% for the
daily dose group. Cocaine abuse was equal for
each group – 22.3% and 21.7% positive urines
in the daily and thrice weekly dose groups.
Self-reports of craving were also higher in the
thrice-weekly dose group. Of interest is the
fact that the plasma levels of buprenorphine
were similar in both groups.
The authors concluded that the dosing
schedule used was probably inadequate
(8mg/day of the tablet calculated as being
equivalent to 5.6mg/day of buprenorphine
solution). However, they suggested that daily
dosing should be continued until the patient 
is stabilised, before changing to a less than
daily dosing regimen. This is in keeping with
the Australian guidelines on buprenorphine
use (Lintzeris et al, 2001; see also Chapter 7). 
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Greater than thrice weekly dosing
schedules
Investigators have evaluated the potential of
administering buprenorphine at even greater
intervals (96 and 120 hour intervals). Petry and
workers (1999) enrolled 26 opioid dependent
subjects in a double blind placebo-controlled
crossover trial, whereby each subject received,
in a random order, the following dosing
regimens for 5 repetitions each – 
(a) a maintenance dose every 24 hours, 
(b) a doubled maintenance dose every 
48 hours, 
(c) a tripled maintenance dose every 72 hours
and
(d) a quadrupled maintenance dose every 96
hours. The maintenance dose was
determined during a period of induction
and was either 4mg/70Kg or 8mg/70Kg
per day.
Only 14 of the subjects completed the study
but, of these, only 5 were dismissed for
continuing illicit opioid abuse. There was no
safety concern with excessive opioid agonist
effects with the quadrupled dose and opiate
withdrawal symptoms were seen at the end of
the dosing period in a similar fashion for each
group (i.e. the magnitude of withdrawal
experienced at 96 hours after the quadrupled
dose was similar to that experienced at 48
hours after the doubled dose).
Although this study involved very small
numbers and was undertaken under
experimental conditions (and therefore could
not be said to be representative of real life
usage), the results suggest that it is possible
from a safety and efficacy perspective to
lengthen the interval between buprenorphine
doses. This could be important for compliance
and proper management of a treatment clinic
– 4 of the subjects, initially enrolled in this
study, had to drop out because of
transportation problems.
Another study (Gross et al, 2001) has evaluated
the efficacy of buprenorphine administered at
intervals of up to 120 hours. Twenty-nine
opioid-dependent subjects were enrolled and,
after a period of induction and stabilisation on
either 4mg/70kg/day or 8mg/70kg/day, 26
were randomised to receive either a quintuple
maintenance dose every 120 hours or a
sextuple dose every 120 hours. This was
continued for 20 days, after which they had a
4-day placebo phase and then crossed over 
to the other treatment regiment for a further
20 days. A test dose of the top dose was
given, in 3 divided doses, before the formal
dosing schedule began to evaluate safety 
and all subjects tolerated the dose. Only 14
subjects completed the study. Seven were
dismissed for illicit drug use and 5 left without
notice. The completers experienced agonist
effects 24 hours after dosing. Significant
subjective withdrawal-related effects were
noted in each dose, from 96 hours onwards.
This study involved limited numbers and 
had a high attrition rate, but it reinforced the
safety of buprenorphine at high single doses
(the highest single dose administered was
76.4mg to the opioid-dependent subjects) 
and suggested that the maximum dosing
interval was 96 hours.
In summary, several studies have been
undertaken to identify the optimal dosing
regimen for buprenorphine in its use in the
maintenance treatment of opioid dependency.
These studies have methodological problems,
either in terms of design, small numbers studied
and/or study dosing. Furthermore, although
several studies used a “flexible” dosing regimen,
this did not involve individual titration of dose.
However, the results support the usefulness of
buprenorphine, but it is not possible to identify
the optimal dose. The studies also showed that
it was possible to use a less than daily dosage
administration in this indication, which should
be of use in clinical practice.
5.2.6 Other studies on 
the effectiveness 
of buprenorphine
Few non-randomised studies examining the
effectiveness of buprenorphine in the
management of opioid dependency have 
been reported. Strain et al (1996) performed 
a follow-up analysis of their clinical trial from
1994 that was included in the meta-analysis.
This reported on the subset of 86 patients
(from 164) who remained on treatment
throughout the whole study period. They
found similar effects on urine test results
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between the two groups and a decreased
trend in positive tests over time in the
buprenorphine group, although this finding
was non-significant. 
O’Connor et al (1998) enrolled 46 subjects 
who were randomly assigned to receive thrice
weekly buprenorphine either in a primary 
care clinic (affiliated with a drug treatment
programme) or in a traditional drug treatment
programme for 12 weeks. No comparator was
used. The results were at least as good for 
the primary care group as for those in the
traditional drug treatment setting. This study
is interesting from the treatment setting point
of view as retention times (78% and 52% for
primary care/traditional treatment
programmes) are similar to those seen in other
studies with daily buprenorphine regimens.
Reisinger et al (1985) was the first
observational study to examine
buprenorphine, but there was no comparison
arm. Thirty-one of the 65 participants enrolled
into the study had abandoned treatment
within 2 weeks, but this was related to the low
initial dose (approximately 2mg/day)
5.2.7 Buprenorphine in
combination with naloxone
Naloxone acts as a competitive antagonist at
the opioid receptors in the central nervous
system, reversing the effects of opioids. It has
no opioid agonist activity of its own.
A combination of buprenorphine and
naloxone (4.1 ratio) has been developed for use
in opioid dependence and is currently under
review by the Food and Drug Administration
(Raisch et al, 2002, see also Chapter 6 Abuse
Liability). The aim of the combination is to
reduce the abuse potential of buprenorphine
without affecting its efficacy as a maintenance
treatment for opioid dependence.
Several preliminary studies have been reported
which evaluated buprenorphine and naloxone
in combination. Harris and workers (2000)
investigated the effects of buprenorphine
alone and in combination with naloxone 
(in 2:1 or 1:1 ratio) in opioid dependent
volunteers who had been stabilised on
buprenorphine for a week. There was no
evidence of precipitated opiate withdrawal
either after sublingual or intravenous doses 
of the combination. The ratio of the drug
combination in this study was not the one
chosen for the tablet formulation.
Fudala et al (1998) investigated the effects 
of a 4:1 combination of buprenorphine and
naloxone administered intravenous to 10
opioid dependent subjects, stabilised on
morphine. The combination produced opioid
antagonist-like effects. The investigators
concluded that these effects should limit its
potential for intravenous abuse. 
Amass and workers (2000) compared the
efficacy of daily versus alternate day
treatment with the buprenorphine/naloxone
combination tablet in 26 opioid dependent
outpatients. No difference was found in terms
of treatment retention and positive urinalysis
between the 2 dosage regimens.
Although these are just preliminary studies,
the results suggest that a combination of
buprenorphine and naloxone may be as
effective as buprenorphine alone in the
management of opioid dependence and 
that it will have less abuse potential.
5.3 Overall summary and
conclusions 
Many clinical trials have been undertaken 
to evaluate the use of buprenorphine in the
management of opioid dependency. In terms
of its use in managed withdrawal, the studies
were too heterogeneous to enable formal
meta analysis to be done but a systematic
review suggested that buprenorphine had
potential in this area.
Similarly, the studies investigating the use of
buprenorphine as maintenance/substitution
treatment used diverse protocols in terms of
(a) dosage regimen (daily versus less frequent
dosing), (b) dosage schedules (fixed versus
flexible) (c) total dosage of buprenorphine 
(2-8mg/day or higher) and (d) the formulation
of buprenorphine used. Moreover, studies
varied in their non-pharmacologic treatment
regimens, which could affect the endpoints
and therefore introduce bias. Nevertheless the
results of a formal meta-analysis performed
on 6 randomised controlled trials, using
methadone as comparator, showed that high
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dose buprenorphine was similar to high dose
methadone in terms of treatment retention
with a small increase in positive urinalysis
relative to methadone. Although the latter
was statistically significant, it was not felt to
be clinically relevant. It was not possible to
determine the optimal dosing regimen
although it was noted that less than daily
dosing was feasible in clinical practice.
From the data available it was not possible to
determine whether buprenorphine was more
suitable for specific sub-groups. There is some
evidence to suggest that those, with higher
psychosocial and global functioning are more
likely to respond to buprenorphine, but more
studies are required to substantiate this. Data,
available to date, on its use in pregnant
women showed that buprenorphine was
efficacious and safe for both women and
infants but definitive recommendations on
dosing regimens could not be deduced from
the studies undertaken.
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6.1 Post-marketing data
Post-marketing safety data are available from
the UK and France where buprenorphine is
licensed for the treatment of opioid drug
dependence, within a framework of medical,
social and psychological treatment and has
been in use since 1998 and 1996 respectively. 
In the UK, the product licence holder is
undertaking a surveillance study, conducted
under the guidelines for company-sponsored
safety assessment of marketed medicines
(SAMM). This is a non-randomised, non-
interventional, observational study, comparing
the safety of patients treated with Subutex®
and methadone, over the first 6 months of
treatment. The objective of this study is to
evaluate the safety of high dose buprenorphine,
used for substitution therapy. 
The company plans to recruit 200
investigators in several settings – community
drug teams, drug dependency units and
general practice – and to enrol 5,000 opiate
dependent patients, requiring opiate
substitution therapy. Patients will be entered
in the ratio of 4 Subutex®-treated patients for
every 1 methadone patient. The number of
subjects required is based on results from
controlled studies, which showed retention in
treatment for 6 months of 40 – 50%. A total
population of 5,000 would be expected to
result in the required number so that a 20%
difference, if present, could be detected.
Data will be collected at baseline and at 6
months and the main outcomes to be
measured are general health (assessed by the
Opiate Treatment Index – OTI), details on
opiate dependency, usage and employment
status. In addition, details of “serious adverse
events” occurring within the previous 6
months will be collected at the 6 months
time-point. A serious adverse event is an
experience by the patient that results in death,
is life-threatening, requires hospitalisation or
prolongation of existing hospitalisation, results
in persistent or significant disability, or is a
congenital anomaly/birth defect, that occurs
when the patient is on medication,
irrespective of whether or not it is deemed
drug-related or expected by the investigator.
The company has provided an interim report
from this post-marketing study. Since April
2000, 175 sites have been enrolled and 107 of
these have contributed data. A total of 846
patients have been enrolled. Approximately
800 report forms have been received and
validated. Initial evaluation shows that 84 % of
patients are receiving buprenorphine, 70% are
male and the vast majority (97%) are Caucasian.
So far, ten cases of “serious adverse events”
have been reported by the investigators,
including one death (suicide, judged to be
unlikely to be associated with the treatment).
Of these, 2 have been evaluated as being
probably related – one relates to sensory
disturbance, which was reclassified as not
serious and from which the patient recovered
completely with withdrawal of treatment. 
The second relates to “accidental injury” where
the patient fell and injured himself. There was
also evidence of a drug interaction in this case
(concomitant use of benzodiazepines). The
subject did not require hospitalisation and
recovered completely but buprenorphine 
was withdrawn. Two of the remaining adverse
events were thought to be possibly related 
to treatment (withdrawal syndrome and
convulsions) and the remainder were thought
unlikely to be due to the treatment.
There is preliminary information on the
dropouts in the study. These are subjects who
fail to complete 6 months of treatment. The
biggest single reason for this appears to be
failure to attend the clinic (no reason given),
which was recorded in 26% of the dropout
cases. A further 16% changed to detoxification
regimens and the remaining causes (all at less
than 10%) include adverse event, withdrawal
symptoms, left the area, did not like/want
treatment with buprenorphine, and returned
to heroin use.
This study is limited in that it allows for the
collection of minimal data only. Moreover, the
results to hand are preliminary. However, they
support the view that use of buprenorphine
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for the management of opiate addiction 
in normal clinical practice has not produced
any unexpected or unacceptable toxicity.
Information has been retrieved from the
Adverse Drug Reactions Online Information
Tracking (ADROIT) System of the Medicines
Control Agency (MCA) in the UK. This
provided information on all adverse drug
reactions (ADRs) in its database for
buprenorphine from 1977 – 15/05/01. 
A total of 962 reports were received in that
time, outlining 1,952 reactions. The commonest
reported ADRs were nausea (191), vomiting
(337) and dizziness (excluding vertigo n=202).
The next commonest were hallucinations (63),
headache (58) and vertigo (55). Respiratory
depression was noted in only 39 cases and 
4 cases of hepatobiliary disorders were
recorded. Four deaths were reported 
(3 cardiac arrests and 1 acute circulatory
failure) but there are no further details
available for these reports. It is important to
remember that the data relate to all dosage
forms of buprenorphine (i.e. lower dosage
temgesic® as well as Subutex®) and are not
linked to drug usage figures. Although these
data are non-specific, they are important in
that the pattern of ADR reports is in line with
the known pharmacologic profile of
buprenorphine.
Finally, the product Subutex® was marketed in
France from February 1996 and up until August
1997 21 liver/biliary system related adverse
effects in 12 patients were reported
(unpublished data – company clinical expert
report, 1997). Most of these were “hepatitis” 
and were not fatal. There were 2 deaths
reported, due to liver failure. One of these 
had pre-existing hepatitis B and C. The other
presented with hepatitis and hepatocellular
damage, which proved fatal. The summary of
Product Characteristics (SPC) in France was
amended in September l997 to include a warning
about hepatitis and hepatic events. This warning
is also included in the UK SPC as follows:
HEPATITIS, HEPATIC EVENTS: Hepatic
necrosis and hepatitis with jaundice, 
which generally have resolved favourably,
have been reported in patients who use
buprenorphine. Causality has not been
clearly established. When a hepatic event
is suspected and the causality is unknown,
further evaluation is required. If Subutex®
is suspected to be the cause of hepatic
necrosis or jaundice it must be
discontinued as rapidly as the patient’s
clinical condition permits. All patients
should have liver function tests performed
at regular intervals.
6.2 Fatalities with use
The published data on fatalities come from 
a series of case reports, primarily from France.
A lot of work has been done by French
researchers to develop suitable assays for
measuring buprenorphine and its primary
metabolite norbuprenorphine in blood and
body tissues, in order to estimate the
potential at-risk level for a fatal outcome.
Reynaud and workers (1998) reported on a
series of 6 deaths occurring in known drug
abusers in France. Three of the cases had what
were described as “normal” plasma levels of
buprenorphine and norbuprenorphine, while
the other three had high normal levels. All of
the cases had evidence of therapeutic levels
of benzodiazepines – demethyldiazepam and
7-amino flunitrazepam. No traces of other
opiates were detected in the post-mortem
blood, while a moderate ethanol level was
found in 3 cases. 
Tracqui et al (1998) reported on 20 cases 
of fatality in drug users from urban areas in
France. All cases showed normal or slightly
elevated plasma levels of buprenorphine. 
In addition, evidence of psychotropic agents
(especially benzodiazepines) was found in all
of the plasma samples. These workers also
reported on the phenomenon of injecting 
the crushed tablets (designed for sublingual
use) and felt that this contributed to the risk
of a fatal outcome. Both Traqui and Reynaud
recommended that the provisions for
dispensing buprenorphine that pertained in
France at that time should be reviewed.
In 2001, Kintz published a comprehensive
compendium of French fatalities involving
buprenorphine usage from 1996 – 2000.
Toxicologists in France were notified and asked
to provide data for the report. A total of 117
cases from 14 centres were identified and
included in the analysis. This paper excluded
the cases previously reported by Traqui.
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In Kintz’s report, evidence of drug-related
fatality had been found at the site of death 
in 2/3 of cases – empty packages of tablets,
spoons, straws, syringes, other psychotropics.
In addition, half of the subjects showed
needle marks suggestive of intravenous
injection before death. All cases showed post-
mortem signs consistent with death involving
CNS depressants (especially seen in opiate-
related deaths).
The mean plasma levels for buprenorphine
and norbuprenorphine were normal although
there was a wide variation within the group.
All but one case had a concomitant intake of
psychotropic agents. This case was diagnosed
as Mendelson’s syndrome – tracheobronchial
inhalation. Table 6.1 shows the range of
concomitant drugs.
The paper concludes that the risk of death with
buprenorphine is associated with concomitant
use of psychotropic agents and the intravenous
injection of the tablet formulation, which gives
immediate bioavailability of the tablet. It states
that these cases probably represent an
underestimation of the total number of
buprenorphine-related fatalities because not 
all areas of the country were included in the
survey and autopsies were not always requested
in cases of drug-related death. 
Finally, of interest is a case report of an
intentional suicide from France (Gaulier 
et al, 2000) in which several drugs, 
including buprenorphine had been taken. 
High plasma levels of buprenorphine and
norbuprenorphine were found and the site of
death suggested that the drug had been taken
orally. Therefore, it is possible to get toxic
levels after oral intake.
It is important to note that in France, physicians
may prescribe a supply of up to 28 days of
buprenorphine for substitution treatment and
many of the papers cite the ready availability 
of relatively large doses of buprenorphine as 
a contributory factor in buprenorphine-related
death (see also Chapter 7).
6.3 Abuse liability
It has been known from its early development
phase that buprenorphine has the potential
for abuse, as it produces opioid-type effects in
animals and humans (Jasinski et al, 1978; Mello
et al, 1981). Since the 1980s a series of papers
from various countries, including Ireland,
(O’Connor et al, 1988) have reported on the
misuse of buprenorphine (which was available
as an analgesic) among problem drug users. 
In 1991, Lavelle and workers reported that
buprenorphine was more frequently misused
than heroin or other opiates among a group
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Table 6.1:
* more than one drug was noted in many cases
Drug Class Drug Name No. of Patients  (N=116*)
Benzodiazepines nordiazepam others 64
others 27
total 91
Neuroleptics cyamemazine 26
others 11 
total 37
Antidepressants tricyclics 8
SSRIs 10
total 28
Narcotics morphine (8 @ toxic levels) 12
codeine 2
methadone 4
pethidine 1
propoxyphene 4
total 23
Ethanol “fatal interaction” 4
(n=78) of Glasgow-based drug addicts. This
paper was of interest in that buprenorphine
misuse was not associated with criminality in
this group in contrast to heroin or other illicit
drug use. The reason for this was thought to
be the ready availability and cheap cost of
buprenorphine in the marketplace, at the time. 
Intravenous injection of buprenorphine was
reported by 81% of patients (n=54) presenting
to a drug treatment centre in New Zealand
during 1990. When a buprenorphine-naloxone
combination was launched in 1991, in the hope
of reducing intravenous misuse, approximately
half of the addicts (n=44) questioned over the
next year stated that they continued to inject
the combination product, even though it
produced withdrawal symptoms in about 
1/3 of the group (Robinson et al, 1993).
Intravenous injection of buprenorphine 
was also reported in Spain in heroin addicts
(n=385) undergoing treatment – more than
60% reported use of buprenorphine at some
time during their period of drug abuse and,
of these, 70% used the intravenous route of
administration (San et al, 1993). Further work
by this group (Torrens et al, 1993) compared
the psychopathological characteristics of
buprenorphine abusers (n=22) with heroin
abusers (n=45) in Spain and found no
significant differences. They suggested that
the reason for the abuse of buprenorphine
was the availability of buprenorphine in the
marketplace. The numbers are small in this
study but the findings support those reported
previously from Scotland.
A survey, carried out among 130 community
pharmacists in South Western France in
1992/1993 into the abuse of prescription
medicines, calculated that buprenorphine had
the third highest addiction potential, coming
after a dextroamphetamine combination and
fenzolone, (a sympathomimetic agent) and
higher than other opiates available on
prescription (Baumevieille et al, 1997). The
investigators based their calculation on the
“abuse rate ratio” (derived from dividing the
abuse rate of a medicine by that of a reference
medicine without addictive potential – in this
case frusemide). Buprenorphine was available
only as an analgesic at the time and was subject
to restriction of prescription and supply in line
with the United Nations recommendations for
drugs with addictive potential.
Most of the recently published information 
on abuse liability comes from France, where
“high-dose” buprenorphine (i.e. higher doses
than previously available for analgesia) was
made available as a standard registered
medication. This allowed it to be prescribed
by any medical doctor, general practitioner
(GP) or specialist, in public or private practice,
both in in-patient and out-patient settings.
Prescription is limited only as follows – 
a special prescription pad for controlled
substances is needed and each prescription 
is valid for a maximum of 28 days’ supply.
(Auriacombe et al, 1999). In June l996, 
4 months after high dose buprenorphine 
was made available for the management 
of opioid addiction, a face-to-face survey 
was conducted at over 2,500 pharmacies
throughout France to get information on the
new drug treatment programme (Auriacombe
et al, 1997). Results showed that pharmacists
considered that buprenorphine was used in
the correct fashion in 80% of cases, with
intravenous injection of the crushed tablet
being suspected in 10 – 15% of cases. More
recent reports suggest that intravenous use 
of the crushed sublingual tablet may occur on
an irregular basis in as many as 20 – 30% of
subjects receiving buprenorphine maintenance
treatment in France (Auriacombe et al, 1999).
Information on the level of abuse of
buprenorphine has also come from several
studies, undertaken in France in recent years 
to review the situation of opioid addiction. 
The SPESUB study was begun in May 1996
(Duburcq et al, 2000). This was a prospective
epidemiological 2-year follow-up study, carried
out among approximately 100 French GPs,
involved in the management of drug abusers.
Each GP was required to include the first 10
opioid drug addict patients to whom he/she
prescribed high dose buprenorphine, with 
a maximum inclusion period of 3 months. 
The study reported that 14% of patients 
who remained in the treatment programme
declared intravenous injection of high dosage
buprenorphine in the previous month, although
their intake of other drugs fell from baseline. 
All of these patients received several days’/
weeks’ supply of buprenorphine at a time. 
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The OPPIDUM is an annual survey, which
investigates drug dependent subjects
attending specialized care centres in France.
This survey is organised by the 6 national
Centres for Evaluation and Information on
Pharmaco-Dependence (CEIPs), under the
responsibility of the Commission for
Narcotics and Psychotropic Drugs/French
Drug Agency. The CEIPs select the co-
ordination centres and supervise the 
survey, which takes place over 4 weeks and
collects socio-demographic data and drug
consumption data for the previous week from
attendees at the clinics. Barrau et al (2001)
reported on the 1998 survey, which involved
46 substance abuse treatment centres and
compared the buprenorphine treated group
with those receiving methadone. It is
important to note that in France, methadone
treatment of opioid dependent subjects is
subject to restriction of initial prescription
from a limited number of specialised hospitals
or specialised treatment units, with follow-up
prescriptions allowed only from general
practitioners who are in contact with these
units (Moatti et al, 1998).
The OPPIDUM survey from 1998 involved 
1,462 subjects with a 99% response rate.
Methadone maintenance was the treatment
used in 424 patients and buprenorphine was
used in 616 patients. The remaining patients
were receiving other forms of treatment and
were not discussed in the Barrau report. It 
was noted that 99% of the methadone group
consumed their dose orally, from a legitimate
source and that 98% took their dose as
prescribed on a daily basis. None reported
intravenous/intranasal administration of
methadone, although 15% reported use of 
at least one other intravenous drug in the
previous week. (The intranasal route is used by
some opioid dependent subjects to take illicit
drugs). In contrast, intravenous/intranasal use
of buprenorphine was reported by 16% and 
4% of the buprenorphine group respectively,
with 8% of their doses coming from an illicit
source. Injection rates were even greater for
subjects described as “outwith” the standard
protocols (i.e. on buprenorphine maintenance
treatment without any formal supervision).
Daily use was reported in 94% of the group 
(p = 0.001 with respect to methadone). Further
analysis of the buprenorphine group showed
that those managed within a GP setting were
more likely to abuse buprenorphine via the
intravenous or intranasal routes. The
investigators pointed out that the study did
not represent the global situation, but they
suggested that the behaviour of maintenance
treatment subjects depends less on the nature
of the maintenance drug than the nature of
delivery and monitoring practices.
It is important to note that the OPPIDUM
survey is subject to several biases, the most
important one being selection bias, as the
centres are not randomly chosen (personal
communication, Dr Auriacombe). In addition,
since the survey is undertaken in treatment
centres and excludes general practice, the
type of patient cannot be said to be
representative of the French treatment
population as a whole. However, it provides
data on a large scale and the results are in
keeping with the information received from
the experts in both France and the UK (see
Chapter 7, Review of buprenorphine use in
Clinical Practice). It supports the need to
ensure close monitoring of the patient and 
to limit take-away dosing until the patient is
stabilised, both medically and socially.
A cross-sectional study, undertaken by 
Obadia and workers (2001) over a 3-day 
period in 1997, analysed the risk of illicit use 
of buprenorphine treatment. A questionnaire 
was offered to individuals at 39 sites where
intravenous drug users had access to syringes,
including pharmacies, needle exchange
programmes and 3 syringe vending machines
(which are located in several urban areas in
France). Of 485 potential participants,
completed questionnaires were returned for
343 (70.7%). A total of 112 respondents (32.7%)
were on buprenorphine maintenance
treatment and 79 of these reported
intravenous injection of buprenorphine during
the previous 6 months. Buprenorphine
injection was also reported in the polydrug
users who were not on maintenance
programmes and therefore had procured
buprenorphine through illicit means. Although
the authors admit that the study had many
limitations, the results support other studies in
terms of the abuse potential of buprenorphine.
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Buprenorphine is not authorised in the USA for
the management of opioid dependence at the
present time. In 1994, buprenorphine was
granted Orphan Drug status in the USA for 
“the treatment of opiate addiction in opiate
users”, but such use is strictly confined to
clinical trials (Henney, 2000). Results from
many of the US trials are reported Chapter 5.
All of the patients entered into these trials
were closely monitored and had supervised
administration of most if not all of their 
doses. Therefore, they would have had little
opportunity to abuse their prescribed
buprenorphine medication. Even those trials
undertaken in primary care settings were
strictly supervised (O’Connor et al, 1998).
However, the abuse potential of buprenorphine
has been recognised by the National Institute
on Drug Abuse in the USA (NIDA 2000), which
has funded much of the buprenorphine
research both at national and international
level. It is now working with its commercial
partners to develop a buprenorphine/naloxone
combination tablet (see Chapter 5, Review 
of Clinical Trials with buprenorphine). A new
drug application is pending in the USA for the
combination tablet (4:1 buprenorphine/
naloxone, Raisch et al, 2002). 
NIDA states that both buprenorphine 
(which is nearing final approval by the FDA –
personal communication, NIDA) and the
buprenorphine–naloxone combination are
likely to be administered through “normal
medical practice settings like physicians’
offices” (NIDA 2000). Legislation was passed 
in 1999 (The Drug Addiction Treatment Act),
which allowed for general practitioners in the
USA to prescribe certain narcotics such as
buprenorphine, for maintenance treatment of
opioid-dependent patients (Raisch et al, 2002).
The likelihood of a more liberal availability of
buprenorphine in the USA has resulted in a
Citizens’ Petition being sent to the FDA
seeking a restricted availability similar to that
with methadone and LAAM (their use for
outpatient treatment is restricted to treatment
programmes that obtain a special licence and
adhere to specific regulations on use –
O’Connor et al, 1998). The final decision by the
FDA on the method of supply and regulation
of buprenorphine use is not yet available.
6.4 Overall summary and
conclusions
The safety data available to date suggest that
buprenorphine has a known and predictable
toxicity profile, related to its opioid agonist
pharmacology and its interactions with other
medicines. Although causality has not been
proven, there is a warning regarding possible
hepatotoxicity associated with use and it is
recommended that liver function tests are
regularly performed in patients receiving
buprenorphine. The biggest problem to date
appears to be the risk of fatal interaction with
benzodiazepines. 
Buprenorphine has a known potential for
abuse, because of its opioid effects. Studies
from France suggest that abuse may occur 
in up to 30% of treatment subjects. It would
appear from these studies that abuse is more
likely in those subjects not closely supervised
either by a physician or dispensing pharmacist.
Since harm reduction is a main aim of all
substitution treatment programmes and
reduction in the use of intravenous injections
an important element of harm reduction, it is
reasonable to conclude that buprenorphine
usage should be subject to supervision by
physician and/or dispensing pharmacist
especially in the early phase of treatment
(induction phase).
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7.1 Use of buprenorphine within
the European Union (EU)
The European Monitoring Centre for Drugs 
& Drug Addiction (EMCDDA) was set up by
Council Regulation (EEC) no 302/93 and became
fully operational in 1995. It is located in Lisbon
and its mission is to provide the EU and member
states with objective, reliable and comparable
information at European level concerning drugs
and drug addiction and their consequences. 
In a recent publication (Farrell et al, 2000) 
the EMCDDA reported that high-dose
buprenorphine (in the form of Subutex®) was
introduced into the substitution treatment
programmes for opioid dependence of many 
EU member states in the late 1990s (including
Denmark, Germany, Italy, Luxemburg, Austria,
Finland and the UK). France was the first
member state to authorise such usage (in 1996)
and the EMCDDA estimated that buprenorphine
treatment had been prescribed to as many as
60,000 opioid dependent subjects over a 5-year
period in France (this figure has now risen to
70,000 – personal communication Dr.
Auriacombe). The authorisation for Subutex® is
pending in Ireland (personal communication,
Irish Medicines Board).*
There have been several observational studies
carried out in France since 1996 and these are
outlined below (see section 7.3). There are no
evaluation data from Denmark, Germany, Italy,
Luxemburg or Finland as usage to date is too
small. Several clinical trials were undertaken 
in Austria in the 1990s and these are reported
elsewhere in this report (see Chapter 5). There
are no data available regarding use in practice
from Austria as there is no public funding
available for surveillance programmes, but it 
is estimated that the average buprenorphine
dosage used is 8-12mg/day (Fischer, 2000).
7.2 Use of buprenorphine in the UK
The UK authorised high dose buprenorphine
(Subutex®) for the management of opioid
dependence in 1998 but methadone continues
to be the mainstay of substitution treatment
(Farrell and Howes, 2000). A post-marketing
surveillance study is currently being
undertaken by the pharmaceutical company
and interim results are reported elsewhere
(see section 6.1). A qualitative study comparing
buprenorphine with lofexidine for managed
withdrawal in a community setting has also
been undertaken and has shown that
buprenorphine is more effective than
lofexidine in terms of completion of
withdrawal and alleviation of withdrawal
symptoms (White et al, 2001).
Two treatment centres (general practice
clinics) in London where buprenorphine has
been used for the management of opioid
dependence were contacted and a
questionnaire on the use of buprenorphine
was sent to the contact physician in each
centre. This was discussed in detail with the
respondent either on a face-to-face basis or
by phone. The replies to the questionnaire
were subsequently verified with each
respondent, before inclusion in this report.
The questionnaire is found in Appendix II 
and the results of the questionnaire are
summarised in Table 7.1.
7.2.1 Reports from 
treatment centres 
Treatment Centre (1) Report
Background note on centre 
Dr. Gerada is a lead GP in the management of
opioid dependency and the Chair of the Royal
College of General Practitioners’ Advisory
group on drug abuse.
Her practice has direct management, at any
one time of approximately 100 drug users.
Furthermore, under the shared care services
system, she oversees management of
approximately 800 drug users, treated in 
other general practice clinics.
The clinic organises full assessment of each
new patient including full physical
examination and urinalysis. Patients are closely
monitored by the physician in the induction
phase (daily/alternate days) with daily
dispensing of medication in the early weeks 
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* Authorisation of Subutex®occured in August 2002, after completion of the review.
of treatment. Administration of the dose is
not supervised. The interval between clinic
visits is increased as the patient becomes
stabilised on the medication. In addition, the
dispensing interval is also increased with time
to a maximum of 1-2 weeks depending on the
motivation and status of the patient.
Urinalysis is performed infrequently. The 
clinic aims to maintain good contact with 
and support for the patient, which helps with
treatment retention.
Use of buprenorphine in practice
Buprenorphine is used both for managed
withdrawal/detoxification and maintenance
treatment. Withdrawal occurs rarely but
buprenorphine has been found to be better
than lofexidine, the alternative treatment 
used here. It is quicker than methadone taper,
but if patients are being changed over from
methadone, the methadone dose has to be
reduced to 30mg/day and the dose carefully
titrated to minimise the withdrawal symptoms,
which nearly always occur. Dihydrocodeine may
also be used for withdrawal and buprenorphine
has been found to be as effective.
Buprenorphine is used primarily for
maintenance treatment. Each patient’s dose 
is individually titrated until he/she is stabilised
on a daily dosage regimen. Alternate
day/thrice weekly dosing is being considered
for the future. A linear dose-response effect
has been noted up to around 20mg. The
majority of patients are stabilised on a dose 
of around 10mg/day.
There appears to be no absolute contra-
indication to use in any group but patients
with psychosocial problems do less well and
methadone is the treatment of preference for
this sub-group. Similarly patients on long-term
heroin/methadone maintenance or those with
a high opiate addiction may do less well.
Patients on medication for HIV, hepatitis C 
and depression have been treated with no ill
effects to date. It is judged to be particularly
suitable for highly motivated patients as it is
not sedating and therefore they feel better
much sooner than with methadone.
Clinical issues with usage
Side effects include insomnia, which can 
be debilitating and which may need
pharmacological management, anxiety, agitation
during the induction phase and a bad taste in
the mouth from the tablet. Depression may
occur during the maintenance but it may also
be due to the underlying opioid dependency.
There are no figures on possible diversion
from the clinic although studies from France
suggest that diversion may occur in up to 
30% of cases. Good interaction between 
the patient and the treatment is thought to
reduce diversion and also injection of the
dose (approximately 10% of cases may do this
on an irregular basis). Buprenorphine is not
used in a patient if there is a suspicion of
possible abuse.
Buprenorphine is thought to be as efficacious
as methadone, the current mainstay of
treatment and safer for the patient. Other
treatments such as naltrexone and slow-
release morphine are used occasionally but
buprenorphine would be considered to be
more efficacious than these modalities.
Overall, it is currently considered for first line
treatment of opioid dependence at this clinic,
the only contra-indications being poor
psychosocial circumstances or the possibility
of abuse.
Treatment Centre (2) Report
Background note on Centre
Dr. Chris Ford is a general practitioner whose
practice looks after approximately 100 drug
users, of whom around 85 are on substitution
therapy.
The team also includes a psychologist and a
“drug worker” who work with the patients at
practice level. Drug workers usually (but not
always) have a paramedical background such
as nursing.
Patients are managed in the clinic from the
initial stage of treatment onwards. Each new
patient is evaluated by the team and urinalysis
(1 or 2 samples) is carried out before treatment
begins. The patient is seen every few days by
the team during the induction phase of
treatment. The interval between visits is
gradually lengthened, as the patient becomes
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stabilised on substitution therapy. Urinalysis 
is performed frequently at the beginning 
and then randomly, about every 2-3 months,
when the patient is stabilised on treatment.
Urinalysis involves a general screen for all
illicit drugs including cocaine, amphetamines
and cannabis.
Patients receive their medication from a local
pharmacy and consumption is not supervised.
In the early stages of induction, a patient
collects his/her dose on a daily basis (take-
aways have to be given in areas where the
pharmacies are not open at weekends). As
treatment progresses, the patient may be
allowed collect his/her medication every 2
days, with the interval gradually extending
rarely to once weekly over time. A twice or
thrice weekly collection is the commonest
pattern for stable patients. More than a week’s
collection is never allowed except for holidays.
Use of buprenorphine in practice
Buprenorphine is used in the clinic for managed
withdrawal/detoxification, although, in practice,
this involves few patients. It is more efficacious
than lofexidine, the other treatment used 
for this indication. It results in a much quicker
and more effective withdrawal than methadone
taper, which often takes several months, is
rarely successful and is unpleasant. Patients
need to be actively managed during the
induction period of 3-4 days, because of the
development of unpleasant symptoms, such as
agitation, diarrhoea and sleep disturbance that
may be quite severe. Patients need to have their
dose carefully titrated to their needs and they
need symptomatic support, otherwise there 
is a high attrition rate (especially noted for
women patients).
Buprenorphine is used less commonly for
maintenance treatment than methadone 
but is judged to be as effective as methadone
in the appropriate person. Currently there
would be a 20:1 ratio in terms of methadone to
buprenorphine usage in the practice and only
2+ years’ experience (in contrast to 15 years for
methadone); therefore, experience is much less
for buprenorphine. Patients’ dosage is titrated
until they are stabilised, within 3-4 days and
then maintained on a daily dosage regimen.
The average dosage used is 12mg/day. Doses
greater than 20mg have rarely been used.
Buprenorphine has been suitable for all groups,
although experience is small with certain
groups. It has proved very useful in young
people who are methadone naïve and are
requesting a short detoxification. It has been
used rarely in pregnant women but there is a
lack of awareness of buprenorphine on 
the part of the other healthcare professionals
dealing with pregnancy and this may interfere
with the treatment regimen. Therefore
methadone is still given in preference to
pregnant women.
Drug interactions are not considered a contra-
indication and in fact benzodiazepines have
been co-prescribed on occasion especially 
in the induction phase of treatment, with no
ill-effects.
Buprenorphine is particularly suitable for 
well-motivated patients who want to be 
not clouded by medication. People who are
working have found it very helpful. 
Clinical Issues with buprenorphine
Side effects, including agitation, sleep
disturbance and anxiety, only seem to 
occur during the induction phase. There is a
bad/bitter taste from the tablet, which may
clear with time.
Diversion is not thought to be a problem but,
because its use is fairly new, the extent of any
diversion is unknown. No patients have been
found to be injecting their dose.
Use of buprenorphine has increased the 
tools available for substitute medication 
and detoxification and has proven useful 
in primary care. Overall, it is thought to be 
a very useful addition and probably as good 
as methadone for maintenance, in certain
individuals, and better than lofexidine for
withdrawal. As more experience is gained a
better insight into whether certain sup-groups
are more suitable for buprenorphine treatment
will be achieved.
7.3 Use of buprenorphine in
France
In 1996, France introduced high-dose
buprenorphine and methadone for use in 
the management of opioid dependency. Since
then it is estimated that 10,000 patients have
been treated with methadone and 70,000 
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with buprenorphine (personal communication
– Dr Auriacombe). France was the first country
in the world to allow use of high-dose
buprenorphine for the treatment of opioid
dependency through the primary care system.
General practitioners are allowed to initiate
treatment with buprenorphine in their practice
and to manage these patients for the duration
of their treatment (Auriacombe, 2000). In
contrast, methadone is subject to greater
restrictions (see section 6.3 Abuse Liability)
and, in general, methadone-maintained 
patients are treated in specialist settings, only
switching to general practice management
when they are judged to have stabilised on
treatment (usually several months after
beginning of therapy).
Since its introduction in February 1996, there
have been many outcome surveys undertaken
in France to monitor the consequences of this
programme. Early surveys showed unwillingness
by GPs to become involved in the management
of opioid dependent patients. Moatti and
workers (1998) interviewed 1,186 GPs randomly
chosen from across France in April 1996. Only
13% of those GPs interviewed were prepared 
to prescribe buprenorphine. Only 7% of those
who had had little or no prior consultations
with intravenous drug users said they would
prescribe buprenorphine. 
In May 1997, a survey of 200 GPs showed that
26% of them had prescribed buprenorphine but
in the majority of cases, they had treated fewer
than 5 patients. (Bouchez and Vignau, 1998). 
This survey also interviewed over 2,000
pharmacists of whom 52% had dispensed 
a substitution agent of some form in the
previous months. Buprenorphine dispensing 
was supervised in 40% cases only and the
survey reported poor communication between
the pharmacist and prescribing doctor. 
Co-prescription with benzodiazepines was
reported as “infrequent” although injection 
kits were bought at the same time as
buprenorphine in 30% of cases suggesting
intravenous abuse. 
This survey was of particular interest because 
it collected data from 749 patients within the
programme, using a questionnaire, distributed by
GPs and pharmacists. Most of the respondents
had attempted rapid detoxification an average 
of 3 times prior to the introduction of the
maintenance programme. The mean dose of
buprenorphine was reported to be 11mg/day,
with 8% admitting to using the intravenous route.
Over half of the group felt that they were “taking
care of their health” by being in the programme
and almost all of them (95%) reported
improvements in psychosocial status. Although
the method of collection of these data is open
to criticism, the results were encouraging,
especially with respect to the apparent
improvement in the patient’s wellbeing. 
Vignau and workers (2001) undertook an in-
depth review of the health insurance records
for a semi-rural area of northern France, and
identified cases where Subutex® had been 
used over the first two years of use (1996 – 8). 
The GP and pharmacist in each case were
identified and asked to take part in an
interview during which a detailed
questionnaire was completed.
A total of 154 patient records were identified 
of which 142 (92%) were eligible for review. The
survey noted that 27.5% of physicians and 51.8%
of pharmacists in the area were involved in the
treatment programme. During induction, 71% 
of Subutex®doses were supervised by the
dispensing pharmacists (despite there being no
legal requirement to do so and no additional
payment for providing this service). This reduced
to 23% supervised dispensing when the patients
had stabilised on treatment. The mean dose
prescribed was 6mg/day. This is now judged to
be a sub-optimal dose, but probably reflected
the lack of training for GPs at the time and the
concerns of over prescribing high dose opiates.
However, retention rates of 61% were noted at
the end of the observation period (mean
treatment follow-up of 61 weeks). These were
associated with improvements in the patients’
overall medical and psychosocial status, with 
the exception of improvement in depression.
Urinalysis was not routinely performed
(logistically difficult and expensive) and therefore
it was not possible to give an objective
evaluation of illicit opiate use with treatment.
The investigators concluded that the results
were promising but highlighted the need for
specific training (e.g. in terms of correct dosing
and toxicological analysis) for GPs involved in
the management of opioid dependency. 
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The SPESUB study was begun in May 1996 
and was a prospective epidemiological 2-year
follow-up study carried out among 100 French
GPs, involved in the management of opioid
dependency. Each GP enrolled the first 10
patients prescribed high dose buprenorphine
(Duburcq et al, 2000; Fhima et al, 2001) in
his/her practice. Standardised information 
on the patients such as social circumstances,
illicit drug use and the doses of buprenorphine
was collected at 1, 3, 6, 12 and 24 months. The
main outcomes were treatment retention and
follow up by the same GP at 2 years.
Of 919 patients enrolled in the study, 909 were
eligible for evaluation at 2 years. Nearly 70%
of the patients remained within a maintenance
treatment programme – 508 (55.9%) were still
under the care of the enrolling physician with
101 (11.1%) under the care of another healthcare
professional. Among the patients followed by
the same GP, the median dose was 8mg/day
although the dose range widened over the 
2 years. Declaration of heroin and other illicit
drug intake was significantly reduced at 
2 years with social conditions such as housing
and employment significantly improved,
although intravenous injection of
buprenorphine was declared in 14% of
patients. Evidence of reduced drug-related
harm was noted in terms of reduction in the
predicted numbers of seroconversions for
hepatitis B, C and HIV.
This study highlighted the benefit of
buprenorphine in terms of patient wellbeing 
and showed the importance of good interaction
between the patient and physician/treatment
team in order to retain the patient in treatment.
The OPPIDUM is an annual survey, undertaken
in October each year, to investigate drug-
dependence in France (for background details
see section 6.3 Abuse Liability). Several
different reports have been published on the
OPPIDUM studies. Thirion and workers (2001)
recently compared the results of the 1995
survey (which predates the introduction of the
buprenorphine and methadone maintenance
programmes) with those from 1997, one year
after the programmes began. Approximately
1600 files were reviewed from the survey.
The results showed a marked drop off in the
use of heroin (74% in 1995 versus 25% in 1997).
In addition, the overall use of psychoactive
substances, including benzodiazepines was
significantly lower in 1997 compared with 
1995. Patients maintained on methadone
tended to be older and to consume more
cocaine, cannabis and benzodiazepines than
those on buprenorphine, while the latter group
tended to abuse buprenorphine by intravenous
injection. Sixteen percent of buprenorphine
treated patients were also taking
benzodiazepines (62% via medical prescription).
The problems associated with the OPPIDUM
surveys, in terms of bias and lack of
representativeness, have already been discussed
(section 6.3). However, the results of this
comparison have shown a significant reduction
in heroin abuse as a result of the introduction
of the maintenance programmes and support
the use of both buprenorphine and methadone
for the management of opioid dependence.
A recently published report has evaluated 
the profile of patients treated with
buprenorphine, using computerised data 
on prescriptions extracted from the Social
Security System for reimbursement of
prescriptions (Thirion et al, 2002). This was 
a cross-sectional study, which analysed all
buprenorphine prescriptions sent to the 
Social Security during a 4 month period
(September – December 1999) for a specified
(mainly urban) region in southeast France.
The group reviewed the buprenorphine
demographics of the patients, the doses
prescribed and the identity of the
prescriber(s). In addition, co-prescription 
of benzodiazepines was reviewed.
Overall, 76.6% of all prescriptions had been
coded and were available electronically,
covering 86% of the region’s population. These
identified 2,078 patients who had received at
least one prescription of buprenorphine. The
mean number of prescriptions dispensed per
person was 6 and the mean daily treatment
was 11.5mg (in those patients with enough
prescriptions to allow computation).
Concomitant benzodiazepine consumption
was noted in 43% of patients and on occasions
the benzodiazepine and buprenorphine was on
the same prescription form (exact details not
given). Prescriptions came from GPs in 85% of
the cases, with clinics accounting for 11% and
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Table 7.1: Summary data on buprenorphine use in practice in the UK and France
Buprenorphine London (1) London (2) Bordeaux (1) Bordeaux (2)
Use in withdrawal Yes Yes Rarely No
Useful in withdrawal Yes Yes – –
Use in substitution/ Yes Yes Yes Yes
maintenance treatment
Method of dosing Titrated to Titrated to Titrated to Titrated to
individual individual individual individual
Average daily dose (stabilised) 10mg 12mg 13mg 10mg
Supervised administration No No Yes Yes
Use of thrice weekly dosing No+ No No++ No++
Upper level of dose-response effect 20mg – 32mg 32mg
Use in pregnancy Yes Yes* Yes** Yes**
Use in HIV/Hep C/liver disease Yes Yes Yes Yes
Use with psychotropics Yes Yes Yes Yes
Use in longstanding addicts/ ? ? Yes Yes
high opiate dependency
Risk of diversion ? ? <10 – 30%# ?
Risk of injection of dose 10% ? 10% 10%
Problem drug interactions No No No No
Problem side-effects Insomnia Bad taste Bad taste Constipation/
in mouth in mouth bad taste in
mouth
Discontinuation due to side-effects No No No No
Useful in substitution treatment Yes Yes Yes Yes
Buprenorphine versus methadone Same efficacy, Probably as Same efficacy, Same efficacy,
safer, ? abuse good in safer, more safer, more
suitable abuse abuse
patients potential potential
Legend for Table 7.1
London (1) Dr. Gerada, general practitioner. 
London (2) Dr. Ford, general practitioner. 
Bordeaux (1) Dr. Marc Auriacombe, consultant
psychiatrist.
Bordeaux (2) Dr. Michel de Ducla, general
practitioner.
* in practice buprenorphine is used rarely as the
other healthcare professionals involved in the
care of pregnant women are still unfamiliar with
it and therefore may interfere with the
treatment protocol.
** because of the current legal situation in France
buprenorphine is not started in a pregnant
heroin addict presenting for treatment.
However, a patient who becomes pregnant,
while taking buprenorphine, is allowed to
remain on the treatment.
+ thrice weekly dosing may be introduced in the
future.
++ patients have been offered thrice weekly dosing
but have not accepted it.
# <10% represents figures for this clinic. 30%
diversion is seen in situations where supervised
dispensing is not systematic.
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specialist physicians 4%. A total of 21% of GPs
in the region were involved in prescribing, but
of these 61% had only one or 2 patients on
treatment. These figures are consistent with
other published reports and with the current
involvement of GP’s in the treatment
programmes in France generally (personal
communication, Dr. Auriacombe).
Of interest is the fact that 61% of patients
received their prescriptions from one
prescriber, 22% from 2, 11% from 3-5 and 1%
from more than 5 prescribers. On the basis 
of the number of prescribers used, or a daily
“consumption” of 20mg or more (computed
from the files) the patients were divided into a
“deviant group” a “regular follow-up group”, or
an “occasional consult group”. There were
significant differences between the regular
follow-up and deviant groups in terms of
concomitant use of benzodiazepines, which
was much higher in the deviant group (71.4%
versus 38.5%). It was not possible to identify
the reasons for the higher daily dose of
buprenorphine that the deviant group received
– possibly due to either higher personal
consumption, diversion or purchase for
another person. 
This study has limitations in that it was based
on computerised data and therefore could 
not confirm the actual daily dose consumed 
by the patient (as opposed to dispensed to the
patient). Furthermore it did not cover all of 
the prescriptions written during the period
(76% coverage) and did not include all subjects
within the region (estimated 85% coverage),
which may result in selection bias. Finally some
addicts may not be covered by social security
and therefore would not be included in this
survey. However, the results reaffirm the fact
that only approximately 20% of GPs in France
are involved in the buprenorphine treatment
programme, the majority of whom treat only 
a few patients. In addition, it supports the
findings from previous studies, that deviant
patients are more likely to abuse their
treatment medication and other medications,
which may have safety implications.
Dr Auriacombe, from the University of
Bordeaux, was contacted to seek information
on experience of buprenorphine use in France.
He is an expert in the management of
substance abuse and runs a research-based
substance abuse clinic in the university. He has
extensive experience in the management of
opioid dependent patients. Dr Auriacombe’s
centre was visited, in addition to a local
general practice clinic, which manages opioid
dependent patients, and a community
pharmacy, which operates a system of
supervised dispensing at community level.
Information was gathered from the pharmacy
and the treatment centres, using the
questionnaire (Appendix II) as the basis for
discussion. The replies to the questionnaire
were subsequently verified with each
respondent before inclusion in the report.
Each physician has extensive experience of 
use with buprenorphine. The information from
each centre is included separately, together
with a brief introduction to the clinic set-up.
The findings are summarised in Table 7.1.,
which enables a comparison with the data
collected from the UK treatment centres.
7.3.1 Reports from treatment
centres
Treatment Centre (1) Report
This report relates to the general practice of
Dr. Michel de Ducla, from the city of Bordeaux
in France. 
Background note on clinic
The opioid-dependent patients are seen by 
Dr. Michel de Ducla, GP, in his general surgery.
Approximately 15-20% of his patients are drug
addicts (n=60 at any one time).
Opioid dependent patients are referred by
other doctors or patients or via self-referral. 
In France, GPs can prescribe only buprenorphine
to such subjects (methadone initiation is
restricted to specialist centres). 
At first assessment, the patient has a full
evaluation, including physical examination, 
and urinalysis. At the second visit the results
of the urinalysis are available and the
treatment plan is agreed with the patient 
(this is important) and then initiated.
A pharmacist, who has agreed to supply 
the medication is selected and it is arranged
that the patient gets daily-supervised
administration of the dose (unless the
pharmacy closes on Sunday when they 
must have take-aways). In the early stages of
induction (usually the first 2 weeks) patients
are seen regularly (several times a week) and
the dose titrated according to the individual’s
needs. Close contact maintained between the
pharmacist and the GP, which helps in the
team approach to treatment. 
Urinalysis is difficult in general practice, as it
must be sent to a local laboratory for analysis.
It is the practice to take a urine sample at
every visit – this amounts to several samples
per week in the early induction phase. Only
one sample per week is sent for analysis. After
some months the interval will be lengthened
(as patient visits become less frequent). It is
explained to the patient that this is part of 
the treatment protocol (i.e. a tool by which
treatment is optimised) and therefore it is 
not viewed as a humiliation by the patient.
Supervised administration on a daily basis
usually continues for a minimum of 3 months
(usually longer) in the standard patient but 
this can be altered depending on the patient’s
motivation and need for support. During these
3 months, the patient is usually seen by the 
GP once a week, sometimes every 2 weeks.
Afterwards, the patient can be seen once or
twice a month, depending on how well he is
from the psychological point of view.
This practice is part of a voluntary network 
of GPs in the area (RENAPSUD) who co-operate
with each other by sharing expertise and
information in order to facilitate the opioid-
dependency treatment programme. The
network currently receives no state funding.
Use of buprenorphine in practice
Buprenorphine is used for maintenance/
substitution treatment only of opioid-
dependent patients. It is not currently used 
for managed withdrawal. Because of the legal
restrictions in France, methadone patients can
be treated by GPs only when their management
has been stabilised by a specialist centre and it
is felt that they can now be managed in the
community. No other drugs are used specifically
for the management of opioid dependency.
In the maintenance setting buprenorphine
dose is titrated to the patient’s needs and
administered on a daily basis. Alternate
day/thrice weekly dosing has been offered to
some patients but has not been acceptable to
them. The average dose used is 10mg (range 
6-12mg) although on occasions doses outside
this range have been prescribed. A linear dose
response has been noted up to 32mg in the
one patient who was prescribed this dose.
Each dose is dispensed by a local pharmacy 
on a daily basis with supervised administration.
This is continued until at least 3 months when
the patient’s condition has stabilised enough 
to get regular take-aways (up to a maximum 
of 7 days).
In terms of the patients who are suitable for
buprenorphine, no groups are contra-indicated.
To date, two patients attending the practice
and who are taking buprenorphine, have
become pregnant and have had a normal
pregnancy and delivery, with no problems in
the infant. Patients with psychosocial problems
are more difficult to treat but that is due to
their unstable life circumstances. Likewise,
patients with high opiate requirements or long-
standing dependence can be treated provided
they are sufficiently motivated.
There have been no recorded problems 
with use of psychotropic agents, including
benzodiazepines, which have to be 
co-prescribed on occasions.
Clinical issues with buprenorphine usage
Side effects noted in the early weeks of
treatment include withdrawal symptoms 
(as early as 1-3 days of treatment) and the
patient needs titration of dose and support 
in this phase. During the first month or so,
patients may complain of constipation, 
urinary retention, impotence and excessive
perspiration but these gradually clear
spontaneously. The patients complain of 
a bad/bitter taste from the tablet, which
often lasts indefinitely. None of these results
in discontinuation of treatment.
The introduction of buprenorphine use 
into the general practice setting has not
necessitated a change in the practice
organisation. Opioid-dependent patients are
rarely disruptive – in the initial phase they
may be noisy or dishevelled but this rapidly
disappears once treatment is underway. In fact
it is considered beneficial for the opioid-
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dependent patients to be treated in a general
practice setting, as they are not stigmatised.
Therefore, the visits of these individuals are
spaced throughout the daily schedule, rather
than having a specific clinic for opioid
dependency. The non-opioid dependent
patients have not objected to date and have
not left the practice because of the
attendance of opioid-dependent patients.
The abuse potential is a problem that is
usually linked to poor supervision in the 
initial phases of treatment. It is estimated 
that approx 10% of the clinic’s attendees
would inject and those who do would do 
so on a regular basis.
Drug interactions are not a problem in 
clinical practice – the only possible problem
that might occur is with a patient who 
abuses benzodiazepines in addition to 
taking buprenorphine, but this has not 
been a clinical issue so far.
The only factor, which is thought to be a
contra-indication to the use of buprenorphine,
is severe social deprivation or disturbance. 
It is felt that such patients cannot cope with
the organisation necessary to enrol in the
buprenorphine programme. Such patients
would be referred for specialist clinic
programmes.
The practice mainly deals with buprenorphine
and has very small numbers of patients, who
are stabilised on methadone. There is a big
problem in terms of loss of stability with
methadone when anti HIV or hepatitis C
medication is introduced or changed, but this
is not the case with buprenorphine stability.
The main problem with buprenorphine is the
issue of injection – there have been anecdotal
reports of chemical hepatitis with injection of
buprenorphine and injectors also run the risk
of general adverse effects due to use of the
intravenous route. It is important to note that
buprenorphine injectors tend to do so safely
(i.e. do not use dirty or shared needles) and
therefore do not run the risk of contracting
HIV or hepatitis B or C.
Overall, buprenorphine is judged to be 
a good and safe treatment for those opioid
dependent patients who want to be treated
discreetly in the community.
Treatment Centre (2) report
This report relates to the clinic of Dr.
Auriacombe in the Department of Psychiatry,
Victor Segalen University, Bordeaux II, France.
Background note on clinic 
The clinic was established in the Department
of Psychiatry in the University of Bordeaux. 
It is a research–oriented centre, which has
been involved in the investigation and
treatment of all types of substance abuse for
approximately 20 years. It treats around 250
patients/year in its substitution treatment
programme for opioid-dependent patients.
Patients are referred to the centre from
healthcare professionals, via self-referral or
referral from other patients in the programme.
Patients are fully assessed to determine if they
need treatment. For opioid dependent
patients, the clinic recommends that they are
treated with buprenorphine in the community
(as a first option) by GPs. If possible the
patient’s own GP is used, otherwise a GP
local/known to him/her is found and care is
transferred to that general practice. The clinic
would be available to give general advice on
an ongoing basis if needed and if the patient is
not doing well then he can always be referred
back to the clinic at anytime (i.e. without
going on the waiting list).
Whether the patient is treated in the clinic or
referred to a GP for treatment, he/she is
evaluated by the Addiction Severity Index and
some other research tools. The clinic will
monitor progress for research purposes as well
as for therapeutic reasons.
The clinic manages the majority of patients 
by outpatient maintenance with either
buprenorphine or methadone. The choice 
of medication would be buprenorphine in 
the first instance unless the patient has been
previously treated with buprenorphine and 
has relapsed/not done well. It is also possible
to initiate treatment as an inpatient, if this is
judged to be necessary.
Before treatment starts, the doctor discusses
the goals of treatment with the patient 
and evaluates the patient’s perceptions/
expectations of treatment. The goal of the
clinic is abstinence from problem opioid use –
the timeframe is not discussed, although if
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they ask, patients are told to expect treatment
to last for several years. Patients are counselled
(a psychiatric nurse is assigned to each case)
and a medical social worker helps the patients
in terms of social security (important for
payment for treatment outside of clinic) and
social circumstances (living conditions etc.).
A urine sample is taken at the first visit and
the results are available for the next visit
(when treatment is started).
Treatment is prescribed for daily use with
daily-supervised administration, either at the
clinic dispensary or a community pharmacy, 
in the early phase of treatment (any time up
to 3 months or more).
In the early stages of treatment, take-aways
are only given where local pharmacies are not
available (e.g. on Sunday). They are introduced
gradually once the patient is stabilised, with
the maximum dispensing allowed being 7 days,
except in exceptional circumstances (e.g.
holidays/work commitments). The clinic has
on-site dispensing which is open everyday for
patients. Urine samples are taken each time
the patient is seen in the early phases
(daily/several times a week) but analysed only
once a week – randomly chosen. As treatment
progresses and the patient stabilises, visits to
the doctor are less frequent (weekly and then
fortnightly, then monthly) and a urine sample
is taken on each occasion and analysed.
Patients are told that collection of urine
samples for analysis is part of the treatment
programme and necessary to optimise
treatment. Therefore, it is not seen as a
sanction against the patient. It only becomes 
a tool used for sanction if a patient, who
continually has positive urines, refuses to 
take a higher dose or to return to continue
daily supervised dispensing.
Managed withdrawal/detoxification is used
extremely rarely for patients by the clinic 
(e.g. rare case of recently addicted person 
of a few months and usually not intravenous
abuse). There is a high relapse rate for patients
in general with this treatment and therefore 
it would be reserved for those who have been
on maintenance treatment for several years
and who now wish to discontinue medication.
Since buprenorphine has only been in general
use since 1996, there are few patients on
buprenorphine in this category. It is not the
policy to switch methadone maintained
patients to buprenorphine for withdrawal,
therefore experience is limited. If the patient
demands buprenorphine for withdrawal,
methadone is reduced and the patient is
warned that withdrawal symptoms for the first
few days of buprenorphine are likely. It is not
the policy of the clinic to initiate total
discontinuation of maintenance therapy after
a specific length of stable treatment.
Use of buprenorphine in practice
Buprenorphine is used primarily for
substitution/maintenance treatment. It is 
not recommended for short-term “managed
withdrawal” use and other methods are used
in preference (e.g. electric therapy) but these
are also used rarely in the clinic.
For maintenance treatment in the clinic,
patients are titrated on a daily basis to achieve
optimum level for stability (each individual is
different).
It is important to note that induction begins
when the patient has discontinued heroin 
for long enough to begin to experience
withdrawal (time varies from patient to
patient). The longer the interval between 
the last dose of heroin and first dose of
buprenorphine, the less severe the withdrawal
symptoms are likely to be.
Alternate day/thrice weekly dosing has been
offered to patients, but does not appear to be
acceptable to them and therefore is not used. 
Each dose is dispensed by the clinic
dispensary or community pharmacy and is
supervised – the patient is given a tablet to
put under his/her tongue and is asked to stay
for approximately 10 minutes in the view of
the dispensing pharmacist/clinic nurse to
ensure absorption. If the patient requires more
than one tablet, they may be given separately
or together, depending on the patient and
pharmacist choice. Separate administration of
tablets (done to reduce or minimise diversion)
extends the period of observation. 
When the patient has stabilised and is seen
less frequently by the team, then take-aways
on a regular basis are possible at the patient’s
request (e.g. a patient who has negative urines
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for opiates, for 3 consecutive months, as well
as no other problematic substance use like
alcohol or cocaine). Patients may also opt 
not to have take-aways. These are introduced
gradually up to a maximum of 7 days unless 
a person’s job requires a longer interval of 
14 days. Unless the doctor specifically states 
it on the prescription, a pharmacist can only
dispense 7 days supply at a time, even though
the prescription is allowed for 28 days. It is
important that the supervised dispensing is
viewed as a support for the patient and not 
as a sanction/lack of trust of the patient.
The average dose of buprenorphine is
currently 13mg/day. Approximately 80% of
patients have doses between 8 and 16mg/day.
The minimum dose currently prescribed is
0.2mg and the maximum dose is 32mg/day. 
A linear dose-response effect has been noted
in doses up to 32mg for those individuals that
require it (not often needed). The dose is
titrated according to the level of positive
urines, self-reports of craving and concomitant
increase in tobacco or alcohol consumption
(thought to be a sign of inadequate control).
In general, buprenorphine is suitable for all
groups. However, it is not current policy to 
use buprenorphine in pregnant heroin users
who present for treatment. Buprenorphine is
not recommended for such use at present in
the French product licence and there is much
more experience of use with methadone.
However, if a buprenorphine treated woman
becomes pregnant her treatment is not
changed. To date no adverse effects on the
infant, have been noted in this group.
There is no problem with use of
buprenorphine in patients with HIV, hepatitis C
or liver disease. In fact, it is the view of the
expert that these patients are more easily
managed on buprenorphine than on
methadone. Drug interactions with anti-HIV 
or anti-hepatitis C medication occur less
frequently than with methadone and liver
disease is easily monitored by blood tests. 
To date, no patient has required
discontinuation of buprenorphine because 
of deteriorating liver function.
Neither is there a problem with use of
buprenorphine in patients who are depressed
or those requiring psychotropic medication.
The clinic’s policy is to avoid use of
benzodiazepines in this patient population 
but that is not always possible. There have
been no problems with concomitant use of
benzodiazepines and buprenorphine when 
this has been necessary.
Clinical issues with buprenorphine usage
The clinic is currently undertaking a formal
review comparing use (in terms of safety) of
buprenorphine and methadone since the
treatments were introduced in the 1990s. In
general buprenorphine treatment is associated,
to varying degrees, with withdrawal symptoms
at induction. Patients should be told of this
and supported through this, otherwise they
drop out of treatment. It is usually of short
duration (a few days at most). If the dose used
is too high at the beginning it causes
gastrointestinal upset, which resolves with
reduction of the dose. Patients complain of a
bad taste from the tablet, which may be
transient. None of the side effects would
necessitate discontinuation of treatment. In
this clinic both buprenorphine and methadone
treatments are managed in the same way.
There is a problem with diversion of
buprenorphine to the black market- it is hard
to get exact figures but it may be as high as
30%. Supervised dispensing greatly reduces
this, hence the need to continue supervised
dispensing for many months until the patient
is stabilised both socially and in terms of
opioid abuse.
Some patients inject their prescribed
buprenorphine (as many as 10%). Patients may
inject their take-aways (e.g. the Sunday dose).
The clinic, if it suspects this or if patients tell
the team, maintain a long-term daily
supervised dispensing for those patients. Once
patients begin to inject their buprenorphine
dose, it is unlikely that they will give up this
practice and this may necessitate a change to
methadone.
Drug interactions (either with concomitant
legally prescribed medicines or with illicit
drugs) are not a problem in clinical practice.
The only factor that contra-indicates the use of
buprenorphine in practice is a heroin-dependent
pregnant woman, presenting for the first time 
(as buprenorphine is not recommended for use
during pregnancy in France).
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The main problem in practice with
buprenorphine is the risk of diversion and 
the risk of injection. It is important to note
that self-injection is usually done in a safe
fashion (i.e. it is not associated with risk of
transmission of blood-borne viral disease
through the use of shared needles).
In terms of comparison with other treatment
modalities, buprenorphine is judged to be as
effective as methadone, with fewer side
effects, less interactions and less disruption of
dose when medication for HIV/hepatitis C is
introduced or changed. The clinic uses other
medications such as clonidine, naltrexone and
long-acting morphine patch so rarely that it is
not possible to compare buprenorphine usage
with them.
The overall conclusion is that buprenorphine 
is used in the clinic as first line treatment as 
it is as efficacious as methadone but safer 
and because buprenorphine is more available
in France and therefore more accessible for
patients.
7.3.2 Report on dispensing of
buprenorphine and
methadone in France
Substitution therapy in the 
community setting
Community pharmacists dispense
buprenorphine/methadone for patients who
attend GPs and also for some patients who
attend specialist clinics but opt to receive
substitution treatment at a community
pharmacy in a more convenient location 
to their home or workplace or at a more
convenient time. The patient may seek
agreement from the pharmacy of his/her
choice to dispense substitution treatment 
or alternatively the physician may select a
pharmacy for the patient. Following selection,
the physician telephones the pharmacist to
confirm participation and to inform him/her
of the treatment plan. The physician then
specifies the pharmacy on the prescription.
The physician will usually telephone the
pharmacist in the event of alteration in dosage
or administration schedule. Pharmacists are
encouraged to telephone the physician if they
observe any problems with administration 
e.g. absenteeism, attempts to avoid on-site
consumption, intoxication etc. It is felt 
that collaboration between healthcare
professionals involved in the substitution
programme encourages a successful outcome 
of treatment.
Methadone supply constitutes a heavy
administrative burden for community
pharmacies. Storage must be in a locked safe.
The pharmacist must order a supply for each
individual patient to cover a specified period
usually a week and never any longer then 14
days. Detailed records must be kept of each
dispensing including patient’s name, prescriber’s
name, doses dispensed and whether consumed
on site in the pharmacy or dispensed as a take-
away dose. Any methadone, which has not
been dispensed during the specified period,
must be returned to the wholesaler. All
prescriptions for methadone and all records of
receipt and supply must be kept for 10 years.
In contrast, buprenorphine dispensing requires
much less administrative effort. Prescriptions
must be kept for 10 years, but there are no
other regulations governing documentation.
Supplies are not ordered on an individual
patient basis; rather the pharmacist may keep
a stock for dispensing purposes. There are 
no regulations governing storage. Therefore
buprenorphine constitutes much less of an
administrative burden than methadone for
community pharmacists which may serve as 
an incentive to take on patients. However,
supervision of administration is more time
consuming with buprenorphine. Patients
remain in the pharmacy for five to ten minutes
to allow time for the sublingual formulation 
to be absorbed. Patients are commonly
prescribed more than one tablet, which may
be administered individually (depending on
the preference of the patient and/or
pharmacist). In contrast oral administration 
of methadone liquid is faster, and
consumption is easier to verify by either
conversing with the patient or observing
consumption of water after the methadone.
Pharmacists receive the same remuneration
rate for prescription of methadone or
buprenorphine as for all other medications
and are not paid for time spent supervising
administration. Despite lack of financial
incentives, over 70% of French pharmacies
have dispensed substitution treatment. 
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The patient must attend the physician at least
once a month to receive a prescription but the
pharmacist is obliged to dispense substitution
treatment for a maximum of one week, unless
specified by the physician in exceptional
circumstances e.g. holidays/work commitments.
This would only take place for patients well
stabilised on treatment. In the case of the
Bordeaux clinics, this means the presence of
negative urines for opiates for at least 3
consecutive months, with no other problematic
substance (e.g. alcohol or cocaine).
Substitution therapy in the specialist
clinic setting
Methadone substitution therapy is usually
initiated in the clinic setting. Initially, patients
may have supervised daily doses dispensed on
site at the clinic. Following stabilisation,
patients may be transferred to GPs and
community pharmacies. Some patients who
commence buprenorphine in the clinic setting
have supervised daily administration on site at
the clinic. Others attend community
pharmacies from the beginning for reasons of
convenience of location or opening time.
Patients who have proved difficult to stabilise
in the community setting and hence have been
referred to specialist clinics usually are
dispensed substitution therapy on site.
The hospital pharmacy prepares individual
doses for each patient in advance of clinic
sessions. These doses are dispensed in plastic
bottles and labelled with the patient’s name,
the dose of methadone and date to be
administered. Dispensed doses are stored 
in a locked safe in the clinic. The hospital
pharmacist must adhere to strict regulations
with regard to methadone ordering and storage. 
Buprenorphine is not dispensed on an
individual patient basis in advance of the 
clinic session. Tablets are stored with other
psychotropic medicines in the clinic and
dispensed from stock as required during a
clinic session. During clinic sessions, doses of
methadone and buprenorphine are dispensed
to individual patients by psychiatric nurse
counsellors. Consumption is supervised in an
office setting. Urine samples are provided in
an adjacent lavatory at each clinic encounter
but usually only analysed once weekly in a
random fashion.
There is no central treatment list identifying
all patients in treatment. However substitution
therapy for the vast majority of patients is
100% reimbursed by Social Security insurance.
Each patient has a unique ‘smart card’, which 
is scanned by the pharmacy at dispensing to
facilitate reimbursement. The drug, dosage 
and prescription details are recorded in the
patient’s file on the Social Security database
and therefore duplication of prescribing and
dispensing may potentially be identified from
this database. However, the system is currently
not used routinely to identify patients who
receive substitution treatment both at a
specialist clinic and at a community pharmacy.
7.4 Use of buprenorphine outside
of the EU
Buprenorphine is registered in Australia for use
in the management of opioid dependence.
Clinical trials have been undertaken at a number
of sites across Australia and the results are
expected to be published by early 2002 
(Ali et al, 2001). National clinical guidelines were
developed for the use of buprenorphine, based
on extensive evaluation of the literature and
discussions with experts from the USA and
France (personal communication, Dr Lintzeris).
The guidelines are very detailed and lay out 
the requirements for use of buprenorphine in
practice. Prescription is limited to “medical
practitioners who have recognised knowledge
and skills in the assessment and treatment of
opioid dependent people and knowledge of
clinical guidelines” (Ali et al, 2001). Each
jurisdiction is responsible for a system of
authorising medical practitioners to prescribe
buprenorphine to a particular patient 
(Lintzeris et al, 2001).
Supervised dispensing is recommended,
especially in the induction phase of treatment.
The policy of take-aways varies from jurisdiction
to jurisdiction, but in general the guidelines 
state that uncontrolled access to take-aways
leads to more diversion and increased adverse
consequences and therefore they advise a
cautious approach to their introduction. 
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In terms of dosing, it is recommended that
patients who are stabilised on once daily
dosing should be considered for alternate-day
or thrice weekly dosing, although it is
recognised that not all patients are suitable
for less than daily dosing. The dosage to be
used is calculated as follows:
3-day dose = 3 times the normal 24-hour dose
if the 24-hour dose is < 12mg. 
3-day dose = 32mg if the 24-hour dose is > 12mg.
The guidelines estimate that approximately
15% of patients are more comfortable and
more effectively maintained on daily, rather
than alternate-day or thrice weekly dosing
regimens (Lintzeris et al, 2001). 
Buprenorphine is not recommended for use in
pregnant women, due to insufficient evidence
of its safety, for either the developing foetus
or breast-fed infant (Lintzeris et al, 2001).
The guidelines, which are extremely detailed
were issued in March 2001. A randomised
controlled trial comparing use of
buprenorphine (according to the guidelines)
versus methadone was undertaken in
approximately 20 clinics/general practices 
and the results were comparable in each 
group (personal communication, Dr Lintzeris).
The investigators believe that the results
indicate that the guidelines are “clinician
friendly” and that the use of buprenorphine, 
as recommended in them, is safe and effective. 
Finally, the approval of buprenorphine for the
management of opioid dependence in Australia
has been welcomed because it has less
regulatory control than methadone. This allows
general practitioners to become more involved
in its use, thereby expanding the treatment
programme options and eventually reducing
heroin-related deaths, blood borne viral
infections and reducing crime and corruption,
due to heroin abuse (Wodak and Hall, 2001).
In the USA, buprenorphine is still an
unauthorised medicine, subject to strict
regulation (Henney, 2000). Therefore, there are
no data about use in clinical practice, other
than results from clinical trials, already
reported in Chapter 5, Clinical Trials.
7.5 Summary and conclusions
Buprenorphine is used for the management 
of opioid dependence in several countries
throughout the world. It appears to be safe
and as efficacious as methadone, the
commonest comparator. Although the
treatment regimens and practices vary from
country to country, it appears that patients 
do best when the dose is titrated to their
individual needs. Careful dispensing and
supervision of individual doses reduces the
risk of abuse, which is greater than that seen
with methadone. Although problems with
drug interactions (either with co-prescribed
medications or illicit drugs) might be
expected, based on an understanding of the
pharmacology of buprenorphine, this has not
been seen as a major clinical problem in
practice. In fact, several experts report that
drug interactions are less of a problem with
buprenorphine, compared with methadone.
There is little clinical experience with use in
pregnant women to date. It is considered to
be a useful medication for the management of
opiate dependence by those clinical experts
interviewed, who have used it in practice.
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8.1 Pharmacoeconomic analysis
of the impact of introducing
buprenorphine as an
alternative to methadone
for maintenance therapy of
opiate addiction in Ireland
There are two features that characterise
pharmacoeconomic analysis. Firstly, it
determines both the input (costs) and output
(consequences) resulting from drug intervention.
Second, economic analysis concerns itself with
choices as resource scarcity necessitates that
choices must be made. As a result,
pharmacoeconomic evaluation is frequently a
comparative analysis of alternative courses of
action (in this case methadone versus
buprenorphine therapy) in terms of their costs
and consequences. Although buprenorphine is
not yet licensed in the United States, a recent
pharmacoeconomic analysis of the cost-
effectiveness of buprenorphine maintenance
therapy for opiate addiction in the US
suggested that buprenorphine is cost-effective
at a price of $5 per dose. At $15 per dose it is
cost-effective if adoption leads to an overall
expansion in the numbers engaged in
maintenance treatment (Barnett et al, 2001).
However, a pharmacoeconomic evaluation
carried out in one setting is frequently not
generalisable to another very different
healthcare setting characterised by different
models of care, resource utilisation and unit
costs. Therefore, with reference to the Irish
context as there is no study comparing
methadone with buprenorphine therapy, an
economic model was constructed, which
incorporates health outcome data from the
literature and cost data from the Irish
healthcare setting. A decision tree analysis
format was adopted where probabilities and
payoff values were assigned to each option. 
All options presented for methadone were
duplicated for buprenorphine but the
probability of occurrence differs (depending on
the meta analysis). By rolling back the decision
tree it is possible to demonstrate whether
adopting buprenorphine as an alternative
treatment strategy to methadone is a cost-
effective option in the Irish healthcare system
A decision tree was constructed outlining 
the likely treatment plan with each therapy
(Figure 3). Methadone is currently the
treatment of choice for management of opiate
addiction in Ireland and the treatment plan for
methadone is based on protocols used locally.
Incorporating buprenorphine into current
models for delivery of care formed the basis
for this analysis. Clinical efficacy data was
taken from a meta-analysis of clinical trial
data, which is included in this report and
adapted for local expert opinion on retention
rates. A time horizon of 24 weeks was chosen
for the pharmacoeconomic evaluation as
patients included in studies in the meta
analysis were followed up for 16 – 24 weeks.
Cost estimates were derived from data
supplied by the ERHA and GMS. Medication
costs were taken from published sources with
modification for currency exchange and for
estimated bulk discounts. All assumptions
used in the models are stated explicitly.
The results are presented in terms of cost per
opiate negative patient and cost per patient
retained in treatment at 24 weeks. Analyses 
of two of the models of care delivery i.e.
Health Board dispensing clinic and community
GP/community pharmacy are presented
separately. Sensitivity analysis was carried out
to determine the impact of assuming that the
therapies are equi-effective in terms of
proportion of patients who are opiate
negative and proportion of patients retained
in treatment. The impact of alternative 
dosing schedules i.e. daily versus thrice weekly
buprenorphine was also evaluated. In addition,
the impact of different doses of methadone 
in the community setting was investigated.
Pharmacoeconomics
Chapter 8
Models of delivery of care
Following consultation with local experts, the
treatment plan for each of three models of
delivering care was outlined. In December
2000, 67.6% of patients on the Central
Methadone Treatment List attended specialist
clinics while 32.4% of patients attend GPs
(Building on Experience – Ireland’s National
Drug’s Strategy 2001 – 2008). The three
models described include: 
1. Health Board dispensing clinic 
2. Health Board scripting clinic, dispensed 
by community pharmacist
3. Review in GP surgery, dispensed by
community pharmacist
1. Health Board dispensing clinic 
treatment plan
Two opiate positive urines are required prior
to initiation on the programme. In general,
admission to a programme is constrained 
by waiting lists and limits on the number of
individuals for whom the clinic can provide
treatment. Patients are usually initiated on
20mg of methadone on Day 1. Following
medical review on a daily basis, the dose 
is increased by 10mg per day until the
appropriate dose for the individual has 
been attained. Thereafter,  the doctor 
usually sees the client at least once a week.
The patient attends daily for supervised
administration of methadone for the first 28
days of the programme. Random urinalysis is
carried out twice weekly. If the urine remains
opiate negative at 28 days, the patient is
allowed one take-away dose. If the patient’s
urine remains opiate negative after a further
28 days the patient receives an extra take-
away. As long as the patient’s urine is opiate
negative, this pattern continues until
eventually the patient is in receipt of 6 take-
away doses per week. At this point, frequency
of urinalysis is reduced to once weekly.
Patients who remain opiate negative on 
once weekly attendance may be transferred 
to community GPs for continuity of care.
Consecutive opiate positive urines at any time
during the programme will result in withdrawal
of take-away privileges and return to daily-
supervised doses.
2. Health Board scripting clinic, 
dispensed by community 
pharmacist
The programme followed is very similar to
that of the dispensing clinic except that
patients are reviewed on average twice weekly.
At programme initiation, doses can only be
increased following medical review and
therefore are increased at twice weekly
intervals. Patients receive a prescription, which
is dispensed by their community pharmacy
twice weekly. The community pharmacist
supervises administration of the dose for the
day that the prescription is dispensed and
dispenses take-away doses for the other days.
It usually takes 6 months (6 x 28 days) of
opiate negative urines before a patient is
required to attend only once weekly.
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Figure 3: A decision tree used to determine the cost-effectiveness of methadone and
buprenorphine in the specialist clinic setting using base case parameters.
Cost-effectiveness of
methadone versus
buprenorphine
methadone 
maintenance
buprenorphine 
maintenance
opiate negative over 24 weeks
0.5
opiate positive over 24 weeks
0.5
opiate negative over 24 weeks
0.42
opiate positive over 24 weeks
0.58
retained in treatment 
at 24 weeks
0.6
dropout
0.4
retained in treatment 
at 24 weeks
0.59
dropout
0.41 
3. GP review in GP surgery, dispensed by
community pharmacist
Patients who have been stabilised on once
weekly attendance at the Health Board clinics
may be transferred to community GPs for
continuity of care. These patients are seen
once weekly by the GP, provide a urine 
sample for analysis and are provided with a
prescription for a week’s supply of methadone
to be dispensed at their local community
pharmacy. The community pharmacist
supervises administration of the dose for 
the day that the prescription is dispensed and
provides take-away doses for the other days.
In some cases, usually in areas where Health
Board clinics have not been established, some
level 2 GPs may initiate patients on methadone
maintenance therapy. In general, the programme
as outlined for the scripting clinic is followed
with patients attending on average twice
weekly and receiving prescriptions to be
dispensed by the community pharmacist.
Initially doses are supervised on a daily basis for
28 days. Urinalysis is carried out twice weekly. If
the urine remains opiate negative at 28 days,
the patient is allowed one take-away dose. If
the patient’s urine remains opiate negative after
a further 28 days the patient receives an extra
take-away. As long as the patient’s urine is
opiate negative, this pattern continues until
eventually the patient is in receipt of 6 take-
away doses per week. At this point frequency
of attendance at the GP surgery and urinalysis is
reduced to once weekly.
Decision analytical models were constructed
to represent the first and third modalities of
care delivery as outlined above. Data to
populate these trees may be categorised as
clinical efficacy data, which is common to
both models and economic data, which is
specific to each model of care. The analysis
was carried out from the perspective of the
healthcare provider. Average cost-
effectiveness ratios were calculated for
alternative treatment options.
8.2 Decision analytical model
for Health Board dispensing
clinic treatment plan
The following base case parameter estimates
were used to populate the decision tree
model shown in Figure 3.
Assumptions and Reference Sources for
clinical efficacy base case parameter
estimates (Table 8.1):
1. The probability of opiate negative urine
for each substitution treatment over 24
weeks is based on the mean proportion of
opiate negative urines noted for each drug
in the meta-analysis of clinical trials
comparing the two drugs (Chapter 4). It
has been assumed that the proportion of
opiate negative urines approximates the
probability of opiate negative urine over
the 24 week treatment period.
2. The probability of opiate positive urine = 1
– probability of opiate negative urine.
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Probability of opiate negative urine at 24 weeks: 0.50 1
Probability of opiate positive urine at 24 weeks: 0.50 2
Probability of dropout from treatment at 24 weeks: 0.20 3
Probability of patient with opiate positive urine 0.30 5
and retained in treatment at 24 weeks:
Probability of opiate negative urine at 24 weeks: 0.42 1
Probability of opiate positive urine at 24 weeks: 0.58 2
Probability of dropout from treatment at 24 weeks: 0.24 4
Probability of patient with opiate positive urine 0.34 5
and retained in treatment at 24 weeks:
Methadone: Value Source
Buprenorphine: Value Source
Table 8.1: Clinical efficacy base case parameter estimates
3. The probability of dropout from
methadone treatment at 24 weeks is based
on expert opinion of the Irish clinical
experience.
4. The probability of dropout from
buprenorphine treatment at 24 weeks =
probability of dropout in methadone
treatment X hazard ratio of dropping out for
buprenorphine compared to methadone
taken from the meta-analysis of clinical
trials comparing the two drugs (Table 5.4b).
5. Probability of patient with opiate positive
urine and retained in treatment at 24 weeks
= 1 – probability of opiate negative urine –
probability of dropout from treatment.
Assumptions and Reference Sources for
economic base case parameter estimates
for management in an ERHA dispensing
clinic (Table 8.2):
1. Assume daily methadone dose of 80mg. 
A review of prescriptions for 60 patients
attending one clinic in the South Western
Area Health Board during January 2001
revealed a median dose of 80mg. The
price used was an estimation of the ERHA
contract price at 33% of the standard price
taken from MIMS (September 2001) to
approximate likely bulk discounts.
2. Assume a daily buprenorphine dose of
12mg, which was the median dose, noted
in the final meta-analysis of clinical trial
data and is within the average dose range
used at the Bordeaux site. The price used
was the UK price in sterling (BNF 42,
September 2001) converted to euro.
3. Attendance daily for 4 weeks, then 6 days
per week for 4 weeks, then 5 days per week
for 4 weeks, then 4 days per week for 4
weeks, then 3 days per week for 4 weeks,
then twice per week for the last 4 weeks.
Cost per clinic visit was derived from a top-
down budget estimation of the overall cost
per patient per month attending a single
clinic in the ERHA, which provides
treatment to 43 patients. This estimation
included the cost of medication, staff
(medical, pharmacy, nursing, social work,
administration, outreach, security etc.),
urinalysis, overheads etc. The drug
acquisition cost of 1 month’s methadone 
at 80 mg daily was subtracted from the
above estimate to give a cost per patient
per month excluding methadone. An
attempt to calculate the average number of
clinic visits per patient per month was made
as follows: it was assumed that 50% of
patients attended daily, 10% attended once
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Cost of 24 weeks therapy at 80mg per day €113.68 1
Cost of 24 weeks of clinic visits if opiate negative €17,234.64 3
Cost of 24 weeks of clinic visits if opiate positive €26,809.44 4
Total cost of 24 week programme if opiate negative €17,348.32
Total cost of 24 week programme if opiate positive €26,923.12
Total cost of drop out €13,461.56 5
Methadone: Cost Source
Table 8.2: Economic base case parameter estimates for management 
in an ERHA dispensing clinic
Cost of 24 weeks therapy at 12mg per day €1,301.50 2
Cost of 24 weeks of clinic visits if opiate negative €17,234.64 3
Cost of 24 weeks of clinic visits if opiate positive €26,809.44 4
Total cost of 24 week programme if opiate negative €18,536.14
Total cost of 24 week programme if opiate positive €28,110.94
Total cost of drop out €14,055.47 5
Buprenorphine: Cost Source
8.3 Results from decision analytical model for Health Board dispensing
clinic treatment plan
weekly and the remaining 40% attended
four times weekly resulting in an average of
22.6 visits per patient per month. The cost
per patient per month excluding methadone
was divided by the average number of clinic
visits per patient per month to give an
average cost per clinic visit.
4. Attendance daily for 24 weeks. Cost per
clinic visit was calculated as in 3.
5. Total cost of drop out assumed to be half
the cost of patient with opiate positive
urines attending daily.
Sensitivity analysis
In the base case scenario it is assumed that
buprenorphine is administered on a daily basis.
The average dose of methadone for patients
attending the ERHA clinic is assumed to be
80mg. Efficacy in terms of negative urinalysis
and retention in treatment is based on the
meta-analysis of randomised clinical trial data
with some adaptation for the local setting.
In the sensitivity analysis the impact of
administering buprenorphine three times a
week is explored. In this case it is assumed
that the patient attends daily for the first
seven days to facilitate dose titration and
thereafter attends thrice weekly (Johnson et al
2001). If opiate free the patient attends three
times weekly from week 2 to week 20 and
then twice weekly from week 21 to week 24.
Although the meta-analysis suggests that
buprenorphine may be less effective than
methadone in terms of proportion of negative
urines, this is not thought to be clinically
relevant as the clinical practitioners consulted
in Chapter 7 consider buprenorphine to be 
at least as effective as methadone. Therefore,
the impact of assuming that methadone and
buprenorphine are equally effective was also
determined.
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Average cost per opiate negative patient at 24 weeks €38,886.81 €49,190.44
Average cost per patient retained €24,304.26 €27,328.02
in treatment at 24 weeks
Base case analysis Methadone Buprenorphine
Table 8.3: The cost of treating opiate addiction in an ERHA dispensing 
clinic using either methadone or buprenorphine
(1) Administering buprenorphine thrice weekly:
Average cost per opiate negative patient at 24 weeks €38,886.81 €26,714.96
Average cost per patient retained in treatment at 24 weeks €24,304.26 €14,841.65
(2) Assuming that methadone and buprenorphine 
are equi-effective:
Average cost per opiate negative patient at 24 weeks €38,886.81 €41,024.88
Average cost per patient retained in €24,304.26 €25,640.55
treatment at 24 weeks
Sensitivity analysis Methadone Buprenorphine
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8.4 Decision analytical model
for community based
treatment plan
Assumptions and Reference sources for
economic base case parameter estimates
for management by a community GP and
dispensing by a community pharmacist
(Table 8.4):
1. Assume daily methadone dose of 30mg
based on expert opinion for the Irish
clinical experience. The price used was
taken from MIMS (September 2001).
2. Assume a daily buprenorphine dose of
12mg, which was the median dose, noted
in the meta-analysis of clinical trial data
and is within the average dose range used
at the Bordeaux site. The price used was
the UK price in sterling (BNF 42,
September 2001) converted to Euro.
3. Attendance at GP surgery twice weekly for
24 weeks. Cost per GP visit derived from
the schedule for GP fees (2001 GMS Report
for the year ended 31st December 2000) @
€105.83 per month and added to cost of
urinalysis i.e. urinalysis using “Surestep” kit
twice weekly and by contract laboratory
on average once a month. Cost of urinalysis
was provided by ERHA.
4. Dispensing cost for 24 weeks if opiate
negative: assume supervised dosing at
community pharmacy daily for 4 weeks,
then 6 days per week for 4 weeks, then 5
days per week for 4 weeks, then 4 days per
week for 4 weeks, then 3 days per week
for 4 weeks, then twice per week for the
last 4 weeks. Cost of dispensing was taken
from the current schedule for community
pharmacist fees. 
5. Dispensing cost for 24 weeks if opiate
positive: assume supervised dosing daily
for 24 weeks. Cost of dispensing was taken
from 2000 GMS schedule for community
pharmacist fees (2001 GMS Report for the
year ended 31st December 2000).
6. Total cost of drop out assumed to be half
the cost of patient with opiate positive
urines attending daily.
Cost of 24 weeks therapy at 30mg per day €128.02 2
Cost of 24 weeks of GP visits plus urinalysis €1,192.01 4
whether opiate negative or positive
Dispensing cost for 24 weeks if opiate negative €915.79 5
Dispensing cost for 24 weeks if opiate positive €1,331.91 6
Total cost of 24 week programme if opiate negative €2,235.81
Total cost of 24 week programme if opiate positive €2,651.93
Total cost of drop out €1,325.97 7
Methadone: Cost Source
Table 8.4: Economic base case parameter estimates for management by 
a community GP and dispensing by a community pharmacist
Cost of 24 weeks therapy at 12mg per day €1,301.50 3
Cost of 24 weeks of GP visits plus urinalysis €1,192.01 4
whether opiate negative or positive
Dispensing cost for 24 weeks if opiate negative €915.79 5
Dispensing cost for 24 weeks if opiate positive €1,331.91 6
Total cost of 24 week programme if opiate negative €3,409.29
Total cost of 24 week programme if opiate positive €3,825.41
Total cost of drop out €1,912.71 7
Buprenorphine: Cost Source
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Sensitivity analysis
In the base case scenario it is assumed that
buprenorphine is administered on a daily basis.
The average dose of methadone for patients
attending a community GP is assumed to be
30mg. Efficacy in terms of negative urinalysis
and retention in treatment is based on the
meta-analysis of randomised clinical trial data
with some adaptation for the local setting.
In the sensitivity analysis the impact of
administering buprenorphine three times a
week is explored. In this case it is assumed
that administration is daily for the first seven
days to facilitate dose titration and thereafter
thrice weekly. If opiate negative, the patient
attends for supervised dispensing three times
weekly from week 2 to week 20 and then
twice weekly from week 21 to week 24.
The impact of assuming that methadone and
buprenorphine are equally effective was also
determined. In addition the effect of increasing
the methadone dose to 80 mg is examined to
facilitate a direct comparison with cost of
providing care in the ERHA clinic setting.
8.5 Results of decision
analytical model for
community based
treatment plan
8.6 Discussion and conclusions
This analysis suggests that it is seven to twelve
times more cost-effective to treat opiate
addiction in the community setting than in the
specialist clinic over a 24 week period.
However, this analysis assumes that efficacy
determined from clinical trials carried out in
specialist clinics is maintained in the
community setting. In addition, expenditure
on community care includes fees paid to GPs
and community pharmacies only, whereas the
cost of the specialist clinic service includes
the cost of nursing staff, social workers,
outreach workers, administration and security
staff as well as clinic overheads.
With respect to the base case scenario in 
the ERHA clinic, it is seen that methadone is
more cost-effective than daily buprenorphine
at a cost of €38,886.81 per opiate negative
patient and €24,304.26 per patient retained 
in treatment compared to €49,190.44 and
€27,328.02 respectively. This difference is in
part due to the slightly lower efficacy of
buprenorphine in the meta-analysis but mostly
attributable to the eleven-fold increase in
drug acquisition cost for buprenorphine 
i.e. (€1301.50 for 24 weeks of buprenorphine 
12mg daily compared to €113.68 for 24 weeks
of methadone 80mg daily). Several generic
preparations of methadone are available which
Average cost per opiate negative patient at 24 weeks €3,307.76 €7,425.41
Average cost per patient retained €2,067.35 €4,125.23
in treatment at 24 weeks
Base case analysis: Methadone Buprenorphine
Table 8.5: The cost of treating opiate addiction in the community setting 
using either methadone or buprenorphine.
(1) Administering buprenorphine thrice weekly:
Average cost per opiate negative patient at 24 weeks €3,307.76 €6,281.36
Average cost per patient retained in treatment at 24 weeks €2,067.35 €3,489.64
(2) Assuming that methadone and buprenorphine 
are equi-effective:
Average cost per opiate negative patient at 24 weeks €3,307.76 €6,335.81
Average cost per patient retained in €2,067.35 €3,959.88
treatment at 24 weeks
(3) Increasing the methadone dose to 80mg daily
Average cost per opiate negative patient at 24 weeks €3,691.80 €7,425.41
Average cost per patient retained in €2,307.38 €4,125.23
treatment at 24 weeks
Sensitivity analysis: Methadone Buprenorphine
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facilitates the negotiation of bulk discounts 
by the clinic. If buprenorphine is licensed in
Ireland for management of opiate addiction, 
it will be protected by patent from generic
competition for several years.
The difference in cost-effectiveness between
options is even more exaggerated in the
community setting where methadone costs
€3,307.76 per opiate negative patient and
€2,067.35 per patient retained in treatment
compared to €7,425.41 and €4,125.23
respectively for buprenorphine. This greater
difference may be explained by the fact that
drug acquisition accounts for a much greater
proportion of total cost in the community
setting than in the specialist clinic (7.7% for
methadone and 41.7% for buprenorphine in 
the community compared to 0.6% and 6.3%
respectively in the ERHA clinic).
The patterns observed in the base case
scenario changed little in the sensitivity
analysis when we investigated the impact of
considering both treatment options to be
equally effective (cost-minimisation analysis).
This was not unexpected as the difference in
proportion retained in treatment in the meta-
analysis was not statistically significant and
the difference in proportion of opiate positive
urines noted in the meta-analysis although
statistically significant was small and not
considered to be clinically relevant. This
analysis therefore highlights the impact of
high drug acquisition cost associated with
buprenorphine.
We also investigated the impact of prescribing
buprenorphine three times weekly rather than
daily in both models of care delivery. In the
specialist clinic setting, buprenorphine became
more cost-effective than daily methadone when
administered three times weekly, due to the
saving in expensive clinic visits. Thrice weekly
administration of buprenorphine remained less
cost-effective than daily methadone in the
community setting as there is no impact on cost
of GP care which is reimbursed on a capitation,
rather than fee for service basis, and saving on
community dispensing fees is of a small order of
magnitude i.e. €246.91 per 24 weeks per opiate
negative patient. In addition, any savings on
community dispensing fees may be negated
should community pharmacists seek higher
remuneration for supervised dispensing of
buprenorphine in recognition of the longer
supervision period required.
It is seen from this analysis that prescribing of
buprenorphine in the community setting is up
to twelve times more cost-effective than use 
of this agent in the specialist clinic, but remains
twice as expensive as use of methadone
maintenance in the community over a 24 week
time horizon. However, this analysis has been
carried out from the healthcare provider
perspective i.e. direct medical costs only and
savings on care for complications of illicit
intravenous drug use including HIV and
Hepatitis C have not been included. When
consideration is taken of the fact that
buprenorphine is potentially a safer option, 
and easier to use than methadone, and if the
broader societal perspective is adopted i.e.
benefits of expanding the treated cohort are
included, such as savings on criminal justice
costs and on lost productivity, then
buprenorphine may well constitute a cost-
effective option for the management of opiate
addiction in this country, especially in the
community setting. Utilising a thrice-weekly
administration regimen for buprenorphine
would greatly enhance its cost-effectiveness 
in the specialist setting. A reduction in the
number of clinic visits would potentially allow
a greater number of individuals to be treated 
in a clinic but this advantage may be limited 
by the increase in time required to supervise
administration of buprenorphine compared 
to methadone.
The results from the pharmacoeconomic
evaluation of the use of buprenorphine in the
management of opiate dependence syndrome,
show that use of buprenorphine appears to be
less cost-effective than the current methadone
system. It may prove to be a cost-effective
treatment option in selected Irish settings, but
further studies are needed to identify these
settings.
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Illicit opiate use became a public health problem
in Ireland in the early 1980s. Methadone
maintenance has been available since the l990s
and is the mainstay of treatment in Ireland. A
review was undertaken on the effectiveness of
buprenorphine as a form of treatment for opiate
addiction. A systematic review of all available
data, retrieved from the literature, was
undertaken. In addition, experts who have
experience in the use of buprenorphine, were
interviewed to evaluate the practical issues
associated with the use of buprenorphine.
Economic data were reviewed to estimate the
costs of such usage in the Irish setting.
The results of the review may be
summarised as follows:
1. Buprenorphine has been evaluated for 
use in managed opioid withdrawal
(detoxification) and has been seen to be 
at least as effective as the currently used
treatment modalities (clonidine and
lofexidine). It was not possible to identify
the most appropriate treatment regimen
(either in terms of dosage or treatment
duration) because of the heterogeneity 
of the studies reviewed. 
2. Buprenorphine appeared to be at least as
effective as methadone, when used in the
maintenance/substitution treatment of
opiate dependence (in terms of treatment
retention and positive urinalysis). It was not
possible to identify the most appropriate
treatment regimen but it was noted that in
general, doses of greater than 8mg/day
were needed. 
3. It is not possible to make definitive
statements about its use in specific
subgroups but it appears that responders
are more likely to have higher baseline
levels of psychosocial functioning. 
4. Less than daily dosing (e.g. thrice weekly)
has been shown to be as effective 
(in terms of treatment retention and
positive urinalysis) as daily dosing, using
comparable total weekly doses, although
this may not be suitable for all subjects.
5. Buprenorphine is most effective when 
the dosage is titrated to the individual
needs and the patients are closely
monitored in the early induction phase
with symptomatic treatment and dosage
adjustments to manage withdrawal
symptoms. 
6. Buprenorphine is not recommended for
use in pregnancy in several countries at
present. However, it has been used in
pregnancy (approximately 100 cases
recorded in the literature to date) with no
ill effect on either the mother or infant.
7. It is capable of being abused, because of its
ability to induce opioid effects. Therefore,
its administration would need to be
supervised in the same way as the current
Irish methadone protocol system. The
commercially available tablet can be
crushed and injected. Supervised dispensing
will mean keeping the patient for up to 10
minutes to ensure full absorption has
occurred from the sublingual site.
Swallowing the tablet results in absorption
from the gut with extensive first pass
metabolism and inactivation.
8. Because of its partial agonist properties 
it is less likely than methadone to cause
withdrawal symptoms after abrupt
discontinuation. This makes it useful 
for subjects who wish to (1) undergo
detoxification or (2) withdraw from a
methadone maintenance programme 
and become opiate-free.
9. Its partial agonist properties may cause
problems when trying to change a
methadone-maintained individual to
buprenorphine therapy as opioid
withdrawal symptoms may occur.
Therefore, methadone levels will need to
be reduced to approximately 30mg/day
prior to the changeover with close
monitoring and management of the
patient in the early phases of
buprenorphine treatment.
Summary and Conclusions
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10. Although the known kinetic profile of
buprenorphine would suggest that there
might be a potential for interaction when
the drug is co-prescribed with a variety of
medications, (including certain anti-HIV
medications), this has not been seen to be
a problem in clinical practice in any of the
treatment clinics evaluated in either the
UK or France. Fatal interactions between
buprenorphine and benzodiazepines
and/or other psychotropic agents have
been reported. However, such interactions
do not appear to be a problem in clinical
practice when these are co-prescribed at
therapeutic doses.
11. The presence of liver disease may alter 
the kinetics of buprenorphine and
warrants particular supervision of the
patient. In addition it is recommended
that liver function is assessed regularly
while taking buprenorphine, because of
the possibility of hepatoxicity. However,
patients with liver disease have been
treated with buprenorphine in clinical
practice, with no deterioration in liver
function due to treatment. 
12. The results from a pharmacoeconomic
evaluation of the use of buprenorphine in 
the management of opiate dependence
syndrome, showed that buprenorphine
appeared to be less cost-effective than
the current methadone system. It may
prove to be a cost-effective treatment
option in selected Irish settings, but
further studies are needed to identify
these settings.
In conclusion, this systematic review suggests
that buprenorphine may be viewed as an
effective treatment option in the management
of opiate dependence syndrome, with an
acceptable safety profile.
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The meta-analysis examined the two measures
that were used in all five studies. Every study
conducted a periodic urinalysis for opiates
and reported the length of time that each
subject remained in treatment. In order to
apply the same analytical methods to all data,
we obtained the original urinalysis and
retention data on the subjects in each of the
individual studies. 
Urinalysis data 
Each subject had an outcome, which was the
number of events (positive urinalyses) divided
by the number of possible events (number of
urinalyses). The urinalysis data of each subject
was characterized by a number between zero
and one. The mean of these values was
determined for each group, and the difference
in group means was found for each study. The
meta-analysis estimated the average size of
this difference. This was the mean difference
between buprenorphine and methadone
treatment groups while participants were still
in treatment. 
We used two different methods of handling
missing urinalyses. The first method treated
missing tests as positive, thereby creating a
complete data set. This assumes that a subject
who missed providing a specimen had been
using illicit opiates. Since we considered only
the period while the subject was retained in
treatment, the assumption was not applied to
tests missed because subjects had dropped
out or had been terminated from the study.
The second method ignored missing values.
This approach is valid if the missing status of
the specimen provides no information – if
subjects who had used illicit opiates were just
as likely to fail to provide a urine specimen as
those who had abstained. 
The difference (Di) in outcomes between the
treatment groups was simply the difference
between the mean percent positive of
subjects in the buprenorphine and methadone
treatment groups. 
We found the variance for these estimates 
for each study (Vi) using the standard deviation
of the buprenorphine (SDb) and methadone
treatment (SDm) groups, and the number of
subjects in each group (nb and nm respectively):
Retention data 
The other outcome measured was the length
of time the subject was retained in treatment.
Since patients were followed only until the
last day of each study, this outcome was
censored by the length of follow-up. We
analysed data from each study with a Cox
proportional hazards model. The regression
used the number of days the subject was
retained as the dependent variable, and a
single independent variable, an indicator
which took a value of 1 if the subject was 
in the buprenorphine treatment group. To
provide a clear interpretation of the effect, 
we expressed the hazard parameter as the
relative risk of discontinuing buprenorphine
treatment compared to methadone.
Details of the Analytical Methodology Used in the Meta-Analysis
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Vi  = +
(nb - 1) SDb
2 + (nm - 1) SDm
2    +
nb + nm - 2
1
nb
1
nm
We used the coefficient from the Cox
proportional hazards regressions as the study
level difference (Di) in outcomes between the
treatment groups. The variance from each
study (Vi) was the square of the standard error
of the Cox regression parameter.
Meta-analysis method. 
We determined the weighted mean different
in treatment effect by using reciprocal of the
variance was used to weight each study. The
weighted mean over all M studies was thus
found as:
The variance of this estimate was:
The 95% confidence interval around the mean
difference was found as:
We also tested the validity of the statistical
assumptions needed to pool data for meta-
analysis. This is a test of the homogeneity of
the effect. The null hypothesis of this test is
that the effect size is the same in all of the
studies, that is, the studies are similar enough
to be pooled. The Q statistic for the
homogeneity of effects is:
This statistic is chi-square distributed with M-1
degrees of freedom. If the test was significant,
then we reject the hypothesis of homogeneity,
and conclude that the data from the different
studies cannot be pooled. If this test was not
significant (if we failed to reject the hypothesis
of homogeneity), then we reported the
weighted mean of the difference between the
buprenorphine and methadone treatment
groups. 
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D  =
Vi
Di
1
M
Vi
1
1
M
V  =
1
Vi
1
1
M
D V1.96-+
Wi (Di-D)
2Q  =
1
M
How often are patients seen (assuming 
a daily dosage regimen for all medications)
(tick for yes as appropriate)
Daily
Alternate days
Weekly
>Weekly
Do patients get each dose on a daily basis
(either at clinic or local pharmacy)?
Yes/No (please delete as appropriate)
If no, do they get majority of doses under
daily supervision with “take-aways” according
to their compliance?
Yes/No (please delete tick as appropriate)
If no, how are their supplies of medication
controlled? (please specify)
How often are urines taken for analysis in
induction phase? (tick for yes as appropriate)
Daily
2-3 per week
Weekly
>Weekly
How often are urines taken for analysis in
maintenance phase? (tick for yes as appropriate)
Daily
2-3 per week
Weekly
>Weekly
Please give a brief description of the clinic set-up in terms of doctor/pharmacist input and whether
patients have dispensing and supervised administration of substitution drug at clinic or local
pharmacy level (irrespective of drug type)
Background Data on Clinic Protocol
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Use of buprenorphine for the Pharmacological Management of Opiate Dependence – 
Questionnaire on Practical Aspects of Usage
Use of buprenorphine
1. Do you use buprenorphine for the
management of opiate dependence?
Yes/No (please delete as appropriate)
2. If yes to 1, do you use it for 
(tick for yes as appropriate)
a) treatment of withdrawal
b) maintenance treatment/
substitution treatment
3. Do you use other therapies for the
management of opiate dependence?
(tick as appropriate)
a) Methadone Yes No 
b) Lofexidine Yes No 
c) Naltrexone Yes No 
d) Naloxone Yes No 
e) Diamorphine Yes No 
f) Other opiate substance 
(please specify) 
g) Other drug (please specify)
4. If buprenorphine is used for treatment of
withdrawal, what dosage regimen is used?
(please specify) 
5. How does buprenorphine compare with
other drug regimens in the treatment of
withdrawal? (tick for yes as appropriate
and assume optimal dosage of
buprenorphine)
a) Equal to comparator regimen(s) 
(please specify)
b) More efficacious
c) Less efficacious
d) Less side effects
e) Less withdrawal symptoms 
f) Other comment (please specify) 
6. In the maintenance treatment setting 
how is buprenorphine prescribed? 
(tick for yes as appropriate)
a) Fixed daily dose 
b) Daily dose according to a 
standard regimen
c) Daily dose titrated to the individual 
d) Alternate day/thrice weekly dosing 
e) Other regimens (please specify) 
7. In the maintenance treatment setting, 
how is buprenorphine administered? 
(tick one or more options as appropriate)
a) Each dose dispensed individually 
by pharmacist in the clinic who
supervises administration to ensure
complete absorption*
b) Each dose dispensed individually 
by pharmacist in the clinic who
doesn’t check absorption
c) Doses dispensed by pharmacist 
in the clinic but allowed to take
dose(s) home for one/more days
(take-aways)
d) Dispensed by local pharmacy on 
a daily treatment basis with
supervision of administered dose 
to ensure absorption*
e) Dispensed by local pharmacy on 
a daily treatment basis without
supervision of administered dose
f) Dispensed by local pharmacy – 
several days’ supply allowed 
(please specify)
g) Other forms of dispensing/
administration (please specify)
h) Other comments on any aspect 
of dispensing practice 
*how is absorption verified? 
8. What is the average dose required for
substitution therapy? (tick as appropriate)
a) 1 – 8mg/day
b) 8 – 12mg/day
c) 12 – 16mg/day
d) 16 – 32mg/day
e) Weekly dosage (in case of alternate
day/thrice weekly administration)
f) Other regimens (please specify) 
Do you notice a linear dose-response for
buprenorphine?
Yes/No (please delete as appropriate)
Any additional comments on this issue 
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9. Is buprenorphine suitable for the
following patient groups? (tick for yes as
appropriate)
a) Males
b) Females
c) Pregnant females
d) Patients on anti-HIV medication
e) Pregnant females on anti-HIV
medication
f) Patients with liver disease
g) Patients currently on methadone
maintenance
h) Patients with high opiate 
requirements
i) Patients with longstanding
dependence 
j) Patients with active/history 
of depression
k) Patients with psychosocial 
problems
l) Patients requiring treatment 
with psychotropics 
(please specify drugs)
Any other group (please specify)
10. If buprenorphine is not suitable for
specific groups in question 9, 
please state the reasons
11. In your opinion, does buprenorphine 
have an advantage over other treatment
modalities in any of the subgroups
outlined in question 9?
Yes/No (please delete as appropriate)
Please give reasons for your answer
Practical/Clinical issues with
buprenorphine usage
12. What are the common side effects
encountered with buprenorphine:
a) in the treatment of withdrawal?
(Used/not used- delete as appropriate) 
b) used as maintenance treatment?
(Used/not used – delete as appropriate) 
Are the side-effects transient/present 
for duration of treatment? 
(delete as appropriate)
Would the occurrence of side-effects
result in the discontinuation of use of
buprenorphine Yes/No? 
(delete as appropriate)
If yes, state circumstances
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13. Does the use of buprenorphine necessitate
a change in the way opiate dependent
patients are managed at clinic level, with
respect to other treatment modalities 
(in terms of prescribing/dispensing/
supervised administration/other)?
Yes/No (delete as appropriate)
Please give reasons for your answer 
14. Is the abuse potential of buprenorphine 
a problem in practice?
Yes/No (delete as appropriate)
Please give reasons for your answer 
In your opinion do many subjects inject
the tablet formulation prescribed as
maintenance/withdrawal therapy
Yes/No (delete as appropriate)
If yes please give estimate of occurrence
a) <10%
b) 10 – 20%
c) 21 – 30%
d) 31 – 40%
e) 41 – 50%
f) 51 – 60%
g) 61 – 70%
h) >70%
Would injection occur on a
regular/irregular basis in these cases?
(delete as appropriate)
15. In general, is the issue of buprenorphine-
drug interactions (either with co-
prescribed drugs/illicit drugs) a problem 
in clinical practice? (see also next question)
Yes/No (delete as appropriate)
If yes, would you describe the problem 
as major/moderate/minor? 
(delete as appropriate)
Please give reasons for your answer 
16. If yes to 15, which drugs are most
problematic? (please number 1 – 7 
with 1 being the most problematic)
a) Benzodiazepines 
(please record specific drug(s) 
if difference between the class) 
b) SSRIs/SRIs 
(please record specific drug(s) 
if difference between the class) 
c) Other anti-depressants 
(please specify) 
d) Neuroleptics (please specify) 
e) Other opiates (please specify) 
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f) Alcohol (please specify details 
of amount, if appropriate) 
g) Other drugs (please specify) 
17. Are there factors which contra-indicate
the use of buprenorphine in clinical
practice (medical/practical/other – 
e.g. risk of illicit usage of buprenorphine)?
Yes/No (delete as appropriate)
Please outline these reasons 
18. Are there any other particular problems
with use of buprenorphine in practice (i.e.
not seen with the other medications used)?
Yes/No (delete as appropriate) 
Please give reasons for your answer
19. How do you rate buprenorphine 
in comparison to other treatment
modalities (assume optimal dosage 
of buprenorphine)?
Methadone:
a) Treatment not used in clinic
b) Equal to methadone
c) Better than methadone
d) Less efficacious than methadone
e) Less side effects
f) More side effects
g) Less abuse potential
h) More abuse potential
i) Better than methadone for some
subgroups (please specify) 
Lofexidine:
a) Treatment not used in the clinic
b) Equal to lofexidine
c) Better than lofexidine
d) Less efficacious than lofexidine
e) Less side effects
f) More side effects
g) Less abuse potential
h) More abuse potential
i) Better than lofexidine for some
subgroups (please specify) 
Naltrexone:
a) Treatment not used in the clinic
b) Equal to naltrexone
c) Better than naltrexone
d) Less efficacious than naltrexone
e) Less side effects
f) More side effects
g) Less abuse potential
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h) More abuse potential
i) Better than naltrexone for some
subgroups (please specify) 
Diamorphine:
a) Treatment not used in the clinic
b) Equal to diamorphine
c) Better than diamorphine
d) Less efficacious than diamorphine
e) Less side effects
f) More side effects
g) Better than diamorphine for some
subgroups (please specify) 
Other opiates/other treatment
modalities (please specify)
a) Equal
b) Better
c) less efficacious
d) less side effects
e) more side effects
f) Better than ……………………………………………… 
for some subgroups (please specify
groups and reasons) 
20. Overall, what is your impression of 
the usefulness of buprenorphine in the
management of opiate dependence? 
Any additional comments you may wish to
make may be included here.
End of Questionnaire
Thank You!
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Note: Patients had access to supportive
counselling but attendance was not measured as
an outcome
BPN = buprenorphine
METH = methadone
db = double blind
dd = double dummy
RCT = randomised control trial
Nos/gp 22/23 BPN/Meth (45 in total)
Doses BPN 2mg/day x 3 weeks & then 
gradually reduced x 4 weeks 
and then placebo x 6 weeks
Meth 30mg/day x 3 weeks & then 
gradually reduced x 4 weeks 
and then placebo x 6 weeks
Trial Duration Total study period 13 weeks
Outcomes Measured • Retention in treatment
• Illicit opioid use
• Symptom score 
(withdrawal symptoms)
Results No difference between 
outcomes measured
But BPN 2mg less able to 
attenuate effects of opioid 
challenge (hyromorphine 6mg 
administered 1/M)
1988 Bickel et al (Am Pharm & Ther) First RCT comparing
BPN & Meth (db)
Individual Summaries of Randomised
Controlled Comparative Trials Reviewed
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Note: Counselling was offered but not required
but percentages attending did not differ 
between groups
Nos/gp 53(BPN) 55/54 (162 in total)
Meth (1+2)
Doses BPN 2/4/8mg on days 1,2,3 & then 
8mg daily up to day 120 (17 weeks) 
followed by gradual reduction 
over 49 days (7 weeks) & then 
11 days of placebo
Meth (1) 20/30/25/20mg on days 1, 2-5, 6-9, 10 
& then 20 mg daily up to day 120 
followed by gradual reduction 
over 49 days & then 11 days of placebo
Meth (2) 20/30/40/50/60mg on days 1,2,3,4,5 
& then 60mg daily up to day 120 
followed by gradual reduction 
over 49 days & then 11 days of placebo
Trial Duration 180 days (120 days induction/maintenance 
& 60 days detoxification)
Outcomes Measured • Retention time on Study 
• Illicit opioid use 
(thrice weekly urine samples)
• Daily self-reported questionnaires 
on withdrawal symptoms
Results BPN & Meth 60 were significantly 
better than meth 20mg in the endpoints 
(neg urine samples & retention in study)
BPN equivalent to Meth 60
No difference in ADRs between groups
1992 Johnson et al (JAMA) RCT comparing BPN & Meth (1)+(2) 
for short-term management 
of opioid dependence (db)
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Note: Non-pharmacologic intervention 
(group therapy) was part of the study but 
no mention made of how the various groups
attended the sessions
Nos/gp BPN 28/28 Meth 34/35 (125/140) in total
Doses BPN (1) 2mg/day for 24 weeks
BPN (2) 2mg/day increasing gradually to 
6mg/day for a total of 24 weeks 
Meth (1) 35mg/day for 24 weeks
Meth (2) 35mg/day increasing gradually to 
65mg/day for a total of 24 weeks
Duration of Trial Total Study period 24 weeks
Outcomes Measured • Treatment retention
• Illicit drug use 
(urinalysis weekly & 
self-reported drug use)
• Self-assessment of opioid 
withdrawal symptoms
Result Methadone at 2 doses was significantly 
better than BPN at 2 doses for retention 
time & opiate-free urines 
No difference in effect between 
2 Meth groups or between 2 BPN groups
1993 Kosten et al (J Nerv Ment Dis) RCT comparing 2 doses of BPN with 
2 doses of meth in the management 
of opioid dependence (db)
77
Note: Weekly detailed Counselling (one-to-one
and group therapy) provided. Attendance was
assessed as part of outcome / endpoint – 
no difference between groups
Nos/gp 84/80 (BPN/Meth) 164 in total
Doses BPN 2/4/6/8mg on days 1,2,3,4 & 
then 8mg daily up to week 16. 
Possible to have increases/decreases 
during this time (increments of 
2mg up to max of 16mg)
Dose tapered by 10% each week 
thereafter until at placebo 
at 26 weeks
Meth 20/30/40/50mg on days 1,2,3,4 & 
then 50mg daily up to week 16. 
Possible to have increases/decreases 
during this time (increments of 
10mg up to max of 90mg)
Dose tapered by 10% each week 
thereafter until at placebo 
at 26 weeks
Trial duration 26 weeks
Outcomes Measured • Retention in treatment
• Compliance 
(clinic attendance & 
counselling contacts) 
• Urinalysis thrice weekly
Result No significant difference in outcomes Note: Mean doses used
8.9mg BPN
54mg Meth
1994 Strain et al (Am J Psy) RCT comparing BPN with meth over 
26 weeks (db/dd) – flexible dosing
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Note: Counselling given on one-to-one basis 
as well as group therapy. Important part of
treatment – one of endpoints measured
Nos/gp 24/27 BPN/Meth 51 in total
Doses BPN 2/4/6/8mg on days 1,2,3,4 & 
then 8mg daily up to 3 weeks
Dose increments (2mg) allowed 
to a max of 4 until week 16 & then 
dose tapered by 10% weekly until 
week 26 when it was zero (placebo)
Meth 20/30/40/50mg on days 1,2,3,4, 
and then 50mg daily up to 3 weeks.
Dose increments (10mg) allowed 
to a max of 4 until week 16 and then 
dose tapered by 10% weekly until 
week 26 when it was zero (placebo)
Trial Duration 26 weeks
Outcomes Measured • Treatment retention (up to week 16)
• Compliance 
(attendance for treatment & counselling)
• Urinalysis thrice weekly
Result No difference between treatments 
in endpoint outcomes. 
No selectivity with regard to 
attenuation of cocaine abuse
1994 Strain et al (Psychopharmacology) RCT comparing efficacy of BPN 
with meth for decreasing cocaine 
use in patients with combined 
opioid & cocaine use (db/dd)
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Note 
1) Counselling (one-to-one) was part 
of protocol
2) This was done to satisfy FDA guidelines 
on evaluations of new drugs (need for
placebo – controlled studies if feasible)
3) This was part of a subsequent (larger) 
study undertaken in this research unit
Nos/gp 60/30/60 BPN 2/BPN 8/Placebo (150 in total)
Doses BPN 2mg/daily on days 1-6 after which a 
dose change (to either of the other 
2 groups) was allowed. This dose 
was continued until day 14.
BPN 2/4/8mg on days 1-3 & then 8mg until 
day 6 when a dose change (as above) 
was allowed. This dose was continued 
until day 14
Placebo 0mg medication on days 1-6 after 
which a dose change as above was 
allowed and this dose was 
continued until day 14.
Trial Duration 14 days
Outcomes Measured • Primary – 
Numbers remaining with 
original dosing schedule
• Secondary – 
Urinalysis (3 samples)
• Self reports of withdrawal
Result BPN–treated patients scored better 
than placebo patients, in terms of 
retention in treatment, 
% of +ve urinalysis.
Males showed greater decrease 
in +ve urines
No significant difference in response 
between 2 doses of BPN was noted.
1995 Johnson et al RCT comparing buprenorphine 
(Drug & Alcohol Dependence) to placebo for treatment of 
opioid dependence (db)
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Note: Counselling provided but not obliged 
to attend. No difference between groups here
Nos/gp 75/75/75 (225 in total)
Doses* BPN 2/4/8mg on days 1,2,3 & 
then 8mg for 52 weeks
Meth (1) 30mg daily for 52 weeks
Meth (2) 30 mg on day 1 increasing by 5mg daily 
up to 80mg which was maintained 
for a total of 52 weeks
*Although a fixed-dosing study there 
was a facility to monitor the adequacy 
of the dose in order to identify 
potential problems.
Such patients were redirected 
to other protocols without 
breaking the study code
Duration of Study 52 weeks
Outcomes Measured • Retention Rates
• Urinalysis (thrice weekly)
• Self reports of craving 
• Self reports of withdrawal symptoms
Results Meth 80mg was significantly better 
than the other 2 groups at 
26 and 52 weeks.
No real difference between 
BPN and Meth 30mg
1996 Ling et al (Arch Gen Psy) RCT comparing fixed dose BPN with 
2 doses of methadone over a 
long-term period (db)
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Note:
Counselling provided and subjects had to attend
one hour per week for group therapy (could be
discharged from study for not attending)
Nos/gp 28/29/30/29 (total 116/ 132 randomised)
Doses BPN (1) 1mg daily for 1 week, 2mg daily 
for 1 week, 4mg daily thereafter 
for the duration of study
BPN (2) 4mg daily for 1 week, 8mg daily 
for 1 week, 12mg daily thereafter 
for the duration of the study
Meth (1) 20mg daily for the duration of the study
Meth (2) 35mg daily for 1 week, 50mg daily 
for 1 week, 65mg daily thereafter 
for the duration of the study
Duration of study 24 weeks
Outcomes Measured • Urinalysis (2-3 times weekly)
• Concurrent cocaine use
• Self reports of illicit drug 
& opioid withdrawal symptoms 
• Retention in treatment
Results BPN 12mg & Meth 65mg Note: Non significant trend for 
significantly superior to lower doses increased illicit drug use in BPN 12mg 
+ve urinalysis: compared with Meth 65mg.
58% BPN 2; 45% Meth 2 Significance unknown.
77% BPN 1; 72% Meth 1
No superior beneficial effect for 
either with regard to cocaine use
1997 Schottenfeld et al (Arch Gen Psy) RCT comparing 2 doses of BPN 
with 2 doses of Meth. over 
a 24 week period (db)
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Note: Psychosocial counselling not compared in
the study
Nos/gp 16/18 BPN/Meth 34 in total
Doses BPN Free dosing schedule used 
(max dose 8mg/day)
Meth Free dosing schedule used 
(no upper unit)
Duration of study 24 weeks
Outcomes Measured • Retention Rates
• Urinalysis (weekly)
Results Less +ve urinalysis in BPN group 
but better retention in Meth group 
(differences not significant)
1998 Eder et al (Eur Addict Res) Randomised control trial comparing 
variable doses of BPN & Meth
Note: Psychosocial counselling not compared in
the study
Nos/gp 29/29 BPN/Meth 58
Doses BPN 4 – 16mg daily (variable dosing allowed)
Meth 30 – 120mg daily
Duration of study 6 weeks
Outcomes Measured • Retention Rates
• Urinalysis (weekly)
• Self reports of craving/withdrawal
Results No differences in Urinalysis results.
Retention rate lower with BPN 
but not significant.
1998 Uehlinger et al (Eur Addict Res) RCT comparing variable doses 
of BPN & Meth (db)
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Note:
• First time BPN tablets used in a clinical trial.
• Psychosocial counselling available but not
compared in study
• Open study
• Patient got “take-aways” and did not have to
attend the clinic daily
Nos/gp 29/31 (total of 60)
Doses BPN 2mg on day one, with a dose titration 
of up to max of 8mg daily for the 
duration of the study
Meth 20mg on day one with a dose titration 
of up to max of 80mg daily for the 
duration of the study
Trial duration 24 weeks
Outcomes Measured • Urinalysis 
(twice weekly x 3 and then weekly)
• Retention rates
Results Methadone group showed significantly 
greater retention rates but the BPN 
“completers” showed significantly lower 
illicit drug use compared with 
meth “completers”
1999 Fischer et al (Addiction) RCT comparing flexible 
doses of BPN with flexible 
doses of methadone in an 
open setting for 24 weeks
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Note:
• Concomitant psychosocial counselling not
mentioned
• Subjects were allowed “take aways” after
week 3 (attended clinic thrice weekly only)
• LAAM has been removed from the market 
in the EU but is still available in the US
Nos/gp 55 per group
Doses BPN Thrice weekly dosing (intricate schedule) 
consisting of dose induction 
(weeks 1 & 2) maintenance (weeks 3-17) 
disposition (18-28) average dose 16-32mg 
Mon and Weds and 24-48mg on Friday
LAAM Thrice weekly dosing with above 
schedule to give 75-115mg Mon 
and Weds and 105-161mg on Friday
Meth Low dose – 20mg daily for study
Higher dose – titrated in above 
schedule to give 60-100mg daily
Outcomes Measured • Retention times
• Urinalysis for illicit drug use 
• Self reports of illicit use/ 
withdrawal symptoms
Result BPN, LAAM and high dose Meth 
significantly better than meth 
20mg for all the study variables
2000 Johnson et al (NEJM) RCT comparing BPN (flexible dose) 
LAAM (flexible dose) with meth 
low and high doses over 
a 17 week period (db)
Note: Weekly 20-minute individual counselling
session provided (not obligatory)
Nos/group 38/34 BPN/Meth 72 in total
Doses BPN 2mg/day increasing every second day 
by 2mg to reach 8mg/day by day 7. 
Maintained on 8mg/day for study
Meth 20mg/day increasing every second day 
by 10mg to reach 60mg/day on day 9. 
Maintained on 60mg/day for study
Duration of Study 26 weeks
Outcomes Measured • Retention in study
• Urinalysis self reports of 
cravings and illicit drug use
Result No significant difference between 
groups in terms of urinalysis, 
retention in treatment or self reports.
2000 Pani et al (Drug & Alcohol Depend) RCT comparing fixed dose of 
BPN with fixed dose of Meth (db)
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Note: Obligatory 1-hour weekly individual
counselling session provided
Nos/group 27/31 BPN/Meth 58 in total
Doses BPN 4mg/day X 3 and then flexible dosing 
up to a maximum of 16mg/day
Meth 30mg/day X 3 and then flexible dosing 
up to a maximum of 60mg/day
Duration of Study 6 weeks
Outcomes Measured • Urinalysis (weekly)
• Retention in treatment
• Self reports of craving
Results Significantly better retention rates 
for Meth. Thought to be due to 
inadequate BPN induction dose. 
Other outcomes similar
2001 Petitjean et al RCT comparing flexible doses 
(Drug & Alcohol Depend) of BPN & Meth (db)
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